<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2904245226
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2024
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Sedafol
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PROPOFOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Emulsion for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        17.00
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPIRO PHARMA LIMITED" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPIRO PHARMA LIMITED
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 2950]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Saudi Amarox
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N01AX10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Sefadol is:</strong></p><p><strong>&nbsp;</strong></p><p>Sefadol is an intravenous general anesthetic and sedation drug for use in the induction and maintenance of anesthesia or sedation. Intravenous injection of a therapeutic dose of Sefadol induces anesthesia, with minimal excitation, usually within 40 seconds from the start of injection (the time for one arm-brain circulation). As with other rapidly acting intravenous anesthetic agents, the half- time of the blood-brain equilibration is approximately 1 minute to 3 minutes, accounting for the rate of induction of anesthesia. The mechanism of action, like all general anesthetics, is poorly understood. However, Sefadol is thought to produce its sedative/anesthetic effects by the positive</p><p>&nbsp;</p><p>modulation of the inhibitory function of the neurotransmitter GABA through the ligand-gated GABAA receptors.</p><p>&nbsp;</p><p>What Sefadol is used for:</p><p><strong>&nbsp;</strong></p><p>Sefadol is an IV general anesthetic and sedation drug that can be used as described in the table below.</p><p>&nbsp;</p><p>Indications for Sefadol</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Approved patient population</strong></p></td></tr><tr><td style="vertical-align:top"><p>Initiation and maintenance of Monitored</p><p>Anesthesia Care (MAC) sedation</p></td><td style="vertical-align:top"><p>Adults only</p></td></tr><tr><td style="vertical-align:top"><p>Combined sedation and regional anesthesia</p></td><td style="vertical-align:top"><p>Adults only (see PRECAUTIONS)</p></td></tr><tr><td style="vertical-align:top"><p>Induction of General Anesthesia</p></td><td style="vertical-align:top"><p>Patients greater than or equal to 3 years of</p><p>age</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of General Anesthesia</p></td><td style="vertical-align:top"><p>Patients greater than or equal to 2 months of</p><p>age</p></td></tr><tr><td style="vertical-align:top"><p>Intensive&nbsp;&nbsp; Care&nbsp;&nbsp; Unit&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (ICU)&nbsp; sedation&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of</p><p>intubated, mechanically ventilated patients</p></td><td style="vertical-align:top"><p>Adults only</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Safety, effectiveness and dosing guidelines for Sefadol have not been established for MAC Sedation in the pediatric population; therefore, it is not recommended for this use (see PRECAUTIONS, Pediatric Use).</p><p>&nbsp;</p><p>Sefadol is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations.</p><p>&nbsp;</p><p>In the Intensive Care Unit (ICU), Sefadol can be administered to intubated, mechanically ventilated adult patients to provide continuous sedation and control of stress responses only by persons skilled in the medical management of critically ill patients and trained in cardiovascular resuscitation and airway management.</p><p>&nbsp;</p><p>Sefadol is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established (see PRECAUTIONS, Pediatric Use).</p><p>&nbsp;</p><p>Sefadol is not recommended for obstetrics, including Cesarean section deliveries. Sefadol crosses the placenta, and as with other general anesthetic agents, the administration of Sefadol may be&nbsp; associated with neonatal depression (see PRECAUTIONS).</p><p>&nbsp;</p><p>Sefadol is not recommended for use in nursing mothers because Sefadol has been reported to be excreted in human milk, and the effects of oral absorption of small amounts of Sefadol are not known (see PRECAUTIONS).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp; Do not use Sefadol:</p><p>Sefadol is contraindicated in patients with a known hypersensitivity to Sefadol or any of Sefadol components.</p><p>&nbsp;</p><p>Sefadol is contraindicated in patients with allergies to eggs, egg products, soybeans or soy products.</p><p>&nbsp;</p><p>Warnings</p><p>Use of Sefadol has been associated with both fatal and life-threatening anaphylactic and anaphylactoid reactions.</p><p>&nbsp;</p><p>For general anesthesia or monitored anesthesia care (MAC) sedation, Sefadol should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. Sedated patients should be continuously monitored, and facilities for maintenance of a patent airway, providing artificial ventilation, administering supplemental oxygen, and instituting cardiovascular resuscitation must be immediately available. Patients should be continuously monitored for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation. These cardiorespiratory effects are more likely to occur following rapid bolus administration, especially in the elderly, debilitated, or ASA-PS III or IV patients.</p><p>&nbsp;</p><p>For sedation of intubated, mechanically ventilated patients in the Intensive Care Unit (ICU), Sefadol should be administered only by persons skilled in the management of critically ill patients and trained in cardiovascular resuscitation and airway management.</p><p>&nbsp;</p><p>Use of Sefadol infusions for both adult and pediatric ICU sedation has been associated with a constellation of metabolic derangements and organ system failures, referred to as Sefadol Infusion Syndrome, that have resulted in death. The syndrome is characterized by severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis, hepatomegaly, renal failure, ECG changes* and/or cardiac failure. The following appear to be major risk factors for the development of these events: decreased oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high- dose infusions of Sefadol (greater than 5 mg/kg/h for greater than 48h). The syndrome has also been reported following large-dose, short-term infusions during surgical anesthesia. In the setting of prolonged need for sedation, increasing Sefadol dose requirements to maintain a constant level of sedation, or onset of metabolic acidosis during administration of a Sefadol infusion, consideration should be given to using alternative means of sedation.</p><p>&nbsp;</p><p>*Coved ST segment elevation (similar to ECG changes of the Brugada syndrome).</p><p>&nbsp;</p><p>Abrupt discontinuation of Sefadol prior to weaning or for daily evaluation of sedation levels should be avoided. This may result in rapid awakening with associated anxiety, agitation, and resistance to mechanical ventilation. Infusions of Sefadol should be adjusted to maintain a light level of sedation through the weaning process or evaluation of sedation level (see PRECAUTIONS).</p><p>&nbsp;</p><p>Sefadol should not be coadministered through the same IV catheter with blood or plasma because compatibility has not been established. In vitro tests have shown that aggregates of the globular component of the emulsion vehicle have occurred with blood/plasma/serum from humans and animals. The clinical significance of these findings is not known.</p><p>&nbsp;</p><p>There have been reports in which failure to use aseptic technique when handling Sefadol was associated with microbial contamination of the product and with fever, infection, sepsis, other life- threatening illness, and death. Do not use if contamination is suspected. Discard unused drug product</p><p>&nbsp;</p><p>as directed within the required time limits (see DOSAGE AND ADMINISTRATION, Handling Procedures).</p><p>&nbsp;</p><p>There have been reports, in the literature and other public sources, of the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C, and HIV) from unsafe injection practices, and use of Sefadol vials intended for single use on multiple persons. Sefadol vial is never to be accessed more than once or used on more than one person.</p><p>&nbsp;</p><p>Pediatric Neurotoxicity</p><p>&nbsp;</p><p>Published animal studies demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term cognitive deficits when used for longer than 3 hours. The clinical significance of these findings is not clear. However, based on the available data, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately three years of age in humans (see PRECAUTIONS, Pregnancy, Pediatric Use; ANIMAL TOXICOLOGY AND/OR PHARMACOLOGY).</p><p>&nbsp;</p><p>Some published studies in children suggest that similar deficits may occur after repeated or prolonged exposures to anesthetic agents early in life and may result in adverse cognitive or behavioral effects. These studies have substantial limitations, and it is not clear if the observed effects are due to the anesthetic/sedation drug administration or other factors such as the surgery or underlying illness.</p><p>&nbsp;</p><p>Anesthetic and sedation drugs are a necessary part of the care of children needing surgery, other procedures, or tests that cannot be delayed, and no specific medications have been shown to be safer than any other. Decisions regarding the timing of any elective procedures requiring anesthesia should take into consideration the benefits of the procedure weighed against the potential risks.</p><p>&nbsp;</p><p>Precautions:</p><p><strong>&nbsp;</strong></p><p><strong>General</strong></p><p><strong>&nbsp;</strong></p><p><strong>Adult and Pediatric Patients</strong></p><p><strong>&nbsp;</strong></p><p>A lower induction dose and a slower maintenance rate of administration should be used in elderly, debilitated, or ASA-PS III or IV patients (see DOSAGE AND ADMINISTRATION). Patients should be continuously monitored for early signs of hypotension and/or bradycardia. Apnea requiring ventilatory support often occurs during induction and may persist for more than 60 seconds. Sefadol use requires caution when administered to patients with disorders of lipid metabolism such as primary hyperlipoproteinemia, diabetic hyperlipemia, and pancreatitis.</p><p>&nbsp;</p><p>Very rarely the use of Sefadol may be associated with the development of a period of postoperative unconsciousness which may be accompanied by an increase in muscle tone. This may or may not be preceded by a brief period of wakefulness. Recovery is spontaneous.</p><p>&nbsp;</p><p>When Sefadol is administered to an epileptic patient, there is a risk of seizure during the recovery phase.</p><p>&nbsp;</p><p>Attention should be paid to minimize pain on administration of Sefadol. Transient local pain can be minimized if the larger veins of the forearm or antecubital fossa are used. Pain during intravenous injection may also be reduced by prior injection of IV lidocaine (1 mL of a 1% solution). Pain on injection occurred frequently in pediatric patients (45%) when a small vein of the hand was utilized without lidocaine pretreatment. With lidocaine pretreatment or when antecubital veins were utilized, pain was minimal (incidence less than 10%) and well-tolerated. There have been reports in the literature indicating that the addition of lidocaine to Sefadol in quantities greater than 20 mg lidocaine/200 mg Sefadol results in instability of the emulsion which is associated with increases in globule sizes over time and (in rat studies) a reduction in anesthetic potency. Therefore, it is recommended that lidocaine be administered prior to Sefadol administration or that it be added to Sefadol immediately before administration and in quantities not exceeding 20 mg lidocaine/200 mg Sefadol.</p><p>&nbsp;</p><p>Venous sequelae, i.e., phlebitis or thrombosis, have been reported rarely (less than 1%). In two clinical studies using dedicated intravenous catheters, no instances of venous sequelae were observed up to 14 days following induction.</p><p>&nbsp;</p><p>Intra-arterial injection in animals did not induce local tissue effects. Accidental intra-arterial injection has been reported in patients, and, other than pain, there were no major sequelae.</p><p>&nbsp;</p><p>Intentional injection into subcutaneous or perivascular tissues of animals caused minimal tissue reaction. During the post-marketing period, there have been rare reports of local pain, swelling, blisters, and/or tissue necrosis following accidental extravasation of Sefadol.</p><p>&nbsp;</p><p>Perioperative myoclonia, rarely including convulsions and opisthotonos, has occurred in association with Sefadol administration.</p><p>&nbsp;</p><p>Clinical features of anaphylaxis, including angioedema, bronchospasm, erythema, and hypotension, occur rarely following Sefadol administration.</p><p>&nbsp;</p><p>There have been rare reports of pulmonary edema in temporal relationship to the administration of Sefadol, although a causal relationship is unknown.</p><p>&nbsp;</p><p>Rarely, cases of unexplained postoperative pancreatitis (requiring hospital admission) have been reported after anesthesia in which Sefadol was one of the induction agents used. Due to a variety of confounding factors in these cases, including concomitant medications, a causal relationship to Sefadol is unclear.</p><p>&nbsp;</p><p>Sefadol has no vagolytic activity. Reports of bradycardia, asystole, and rarely, cardiac arrest have been associated with Sefadol. Pediatric patients are susceptible to this effect, particularly when fentanyl is given concomitantly. The intravenous administration of anticholinergic agents (e.g., atropine or glycopyrrolate) should be considered to modify potential increases in vagal tone due to concomitant agents (e.g., succinylcholine) or surgical stimuli.</p><p>&nbsp;</p><p>Other medicines and Sefadol</p><p><strong>&nbsp;</strong></p><p>The induction dose requirements of Sefadol may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of Sefadol and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output.</p><p>&nbsp;</p><p>During maintenance of anesthesia or sedation, the rate of Sefadol administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (e.g., nitrous oxide or opioids). The concurrent administration of potent inhalational agents (e.g., isoflurane, enflurane, and halothane) during maintenance with Sefadol has not been extensively evaluated. These inhalational agents can also be expected to increase the anesthetic or sedative and cardiorespiratory effects of Sefadol.</p><p>&nbsp;</p><p>The concomitant use of valproate and Sefadol may lead to increased blood levels of Sefadol. Reduce the dose of Sefadol when co-administering with valproate. Monitor patients closely for signs of increased sedation or cardiorespiratory depression.</p><p>&nbsp;</p><p>Sefadol does not cause a clinically significant change in onset, intensity or duration of action of the commonly used neuromuscular blocking agents (e.g., succinylcholine and nondepolarizing muscle relaxants).</p><p>&nbsp;</p><p>No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed in adults. In pediatric patients, administration of fentanyl concomitantly with Sefadol may result in serious bradycardia.</p><p>&nbsp;</p><p>Impairment of Fertility</p><p><strong>&nbsp;</strong></p><p>Female Wistar rats administered either 0, 10, or 15 mg/kg/day Sefadol intravenously from 2 weeks before pregnancy to day 7 of gestation did not show impaired fertility (0.65 and 1 times the human</p><p>&nbsp;</p><p>induction dose of 2.5 mg/kg based on body surface area). Male fertility in rats was not affected in a dominant lethal study at intravenous doses up to 15 mg/kg/day for 5 days.</p><p>&nbsp;</p><p>Pregnancy</p><p><strong>&nbsp;</strong></p><p>RiskSummary</p><p>There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, decreased pup survival concurrent with increased maternal mortality was observed with intravenous administration of Sefadol to pregnant rats either prior to mating and during early gestation or during late gestation and early lactation at exposures less than the human induction dose of 2.5 mg/kg. In pregnant rats administered 15 mg/kg/day intravenous Sefadol (equivalent to the human induction dose) from two weeks prior to mating to early in gestation (Gestation Day 7), offspring that were allowed to mate had increased postimplantation losses. The pharmacological activity (anesthesia) of the drug on the mother is probably responsible for the adverse effects seen in the offspring.</p><p>&nbsp;</p><p>Published studies in pregnant primates demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring when used for longer than 3 hours. There are no data on pregnancy exposures in primates corresponding to periods prior to the third trimester in humans [See Data].</p><p>&nbsp;</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p><p>&nbsp;</p><p>Labor and Delivery</p><p><strong>&nbsp;</strong></p><p>Sefadol is not recommended for obstetrics, including cesarean section deliveries. Sefadol crosses the placenta, and as with other general anesthetic agents, the administration of Sefadol may be associated with neonatal depression.</p><p>&nbsp;</p><p>Nursing Mothers</p><p><strong>&nbsp;</strong></p><p>Sefadol is not recommended for use in nursing mothers because Sefadol has been reported to be excreted in human milk and the effects of oral absorption of small amounts of Sefadol are not known</p><p>&nbsp;</p><p>Driving and using machines</p><p><strong>&nbsp;</strong></p><p>Patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle, or hazardous machinery or signing legal documents may be impaired for some time after general anesthesia or sedation.</p><p>&nbsp;</p><p>Effect of Anesthetic and Sedation Drugs on Early Brain Development</p><p><strong>&nbsp;</strong></p><p>Studies conducted in young animals and children suggest repeated or prolonged use of general anesthetic or sedation drugs in children younger than 3 years may have negative effects on their developing brains. Discuss with parents and caregivers the benefits, risks, and timing and duration of surgery or procedures requiring anesthetic and sedation drugs (see WARNINGS, Pediatric Neurotoxicity).</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Sefadol blood concentrations at steady-state are generally proportional to infusion rates, especially in individual patients. Undesirable effects such as cardiorespiratory depression are likely to occur at higher blood concentrations which result from bolus dosing or rapid increases in the infusion rate. An adequate interval (3 minutes to 5 minutes) must be allowed between dose adjustments to allow for and assess the clinical effects.</p><p>&nbsp;</p><p>Shake well before use. Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing.</p><p>&nbsp;</p><p>When administering Sefadol by infusion, syringe or volumetric pumps are recommended to provide controlled infusion rates. When infusing Sefadol to patients undergoing magnetic resonance imaging, metered control devices may be utilized if mechanical pumps are impractical.</p><p>&nbsp;</p><p>Changes in vital signs indicating a stress response to surgical stimulation or the emergence from anesthesia may be controlled by the administration of 25 mg (2.5 mL) to 50 mg (5 mL) incremental boluses and/or by increasing the infusion rate of Sefadol.</p><p>&nbsp;</p><p>For minor surgical procedures (e.g., body surface) nitrous oxide (60% to 70%) can be combined with a variable rate Sefadol infusion to provide satisfactory anesthesia. With more stimulating surgical procedures (e.g., intra-abdominal), or if supplementation with nitrous oxide is not provided, administration rate(s) of Sefadol and/or opioids should be increased in order to provide adequate anesthesia.</p><p>&nbsp;</p><p>Infusion rates should always be titrated downward in the absence of clinical signs of light anesthesia until a mild response to surgical stimulation is obtained in order to avoid administration of Sefadol at rates higher than are clinically necessary. Generally, rates of 50 mcg/kg/min to 100 mcg/kg/min in adults should be achieved during maintenance in order to optimize recovery times.</p><p>&nbsp;</p><p>Other drugs that cause CNS depression (e.g., sedatives, anesthetics, and opioids) can increase CNS depression induced by Sefadol. Morphine premedication (0.15 mg/kg) with nitrous oxide 67% in oxygen has been shown to decrease the necessary Sefadol injection maintenance infusion rate and therapeutic blood concentrations when compared to non-narcotic (lorazepam) premedication.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp; General</p><p>Adverse event information is derived from controlled clinical trials and worldwide marketing experience. In the description below, rates of the more common events represent US/Canadian clinical study results. Less frequent events are also derived from publications and marketing experience in over 8 million patients; there are insufficient data to support an accurate estimate of their incidence rates. These studies were conducted using a variety of premedicants, varying lengths</p><p>&nbsp;</p><p>of surgical/diagnostic procedures, and various other anesthetic/sedative agents. Most adverse events were mild and transient.</p><p>&nbsp;</p><p>Anesthesia and MAC Sedation in Adults</p><p><strong>&nbsp;</strong></p><p>The following estimates of adverse events for Sefadol include data from clinical trials in general anesthesia/MAC sedation (N=2,889 adult patients). The adverse events listed below as probably causally related are those events in which the actual incidence rate in patients treated with Sefadol was greater than the comparator incidence rate in these trials. Therefore, incidence rates for anesthesia and MAC sedation in adults generally represent estimates of the percentage of clinical trial patients which appeared to have probable causal relationship.</p><p>&nbsp;</p><p>The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established with Sefadol during anesthesia (see below). During MAC sedation clinical trials, significant respiratory events included cough, upper airway obstruction, apnea, hypoventilation, and dyspnea.</p><p>&nbsp;</p><p>Anesthesia in Pediatric Patients</p><p><strong>&nbsp;</strong></p><p>Generally the adverse experience profile from reports of 506 Sefadol pediatric patients from 6 days through 16 years of age in the US/Canadian anesthesia clinical trials is similar to the profile established with Sefadol during anesthesia in adults (see Pediatric percentages [Peds %] below). Although not reported as an adverse event in clinical trials, apnea is frequently observed in pediatric patients.</p><p>&nbsp;</p><p>ICU Sedation in Adults</p><p><strong>&nbsp;</strong></p><p>The following estimates of adverse events include data from clinical trials in ICU sedation (N=159 adult patients). Probably related incidence rates for ICU sedation were determined by individual case report form review. Probable causality was based upon an apparent dose response relationship and/or positive responses to rechallenge. In many instances the presence of concomitant disease and concomitant therapy made the causal relationship unknown. Therefore, incidence rates for ICU</p><p>&nbsp;</p><p>sedation generally represent estimates of the percentage of clinical trial patients which appeared to have a probable causal relationship.</p><p>&nbsp;</p><p>Incidence greater than 1% - Probably Causally Related</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Anesthesia/MAC Sedation</p></td><td style="vertical-align:top"><p>ICU Sedation</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Cardiovascular:</p></td><td colspan="2" style="vertical-align:top"><p>Bradycardia</p></td><td rowspan="5" style="vertical-align:top"><p>Bradycardia</p><p>&nbsp;</p><p>&nbsp;</p><p>Decreased Cardiac Output</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Hypotension 26%</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Arrhythmia [Peds: 1.2%]</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nodal</p><p>1.6%]</p></td><td style="vertical-align:top"><p>[Peds:</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypotension* [Peds: 17%](see also&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL</p><p>PHARMACOLOGY)</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Hypertension [Peds: 8%]</p></td></tr><tr><td style="vertical-align:top"><p>Central Nervous System:</p></td><td colspan="2" style="vertical-align:top"><p>Movement* [Peds: 17%]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection Site:</p></td><td style="vertical-align:top"><p>Burning/Stinging&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or</p><p>17.6% [Peds:10%]</p></td><td style="vertical-align:top"><p>Pain,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic/Nutritional:</p></td><td colspan="2" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipemia*</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory:</p></td><td colspan="2" style="vertical-align:top"><p>Apnea</p><p>(see&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; also&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL PHARMACOLOGY)</p></td><td style="vertical-align:top"><p>Respiratory&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Acidosis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During Weaning*</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Appendages:</p></td><td style="vertical-align:top"><p>Rash&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [Peds:</p><p>Pruritus [Peds: 2%]</p></td><td style="vertical-align:top"><p>5%]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Events without an * or % had an incidence of 1% to 3%</p><p>&nbsp;</p><p>&nbsp;</p><p>*Incidence of events 3% to 10%</p><p>&nbsp;</p><p>&nbsp;</p><p>Incidence less than 1% - Probably Causally Related</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anesthesia MAC Sedation</p></td><td style="vertical-align:top"><p>ICU Sedation</p></td></tr><tr><td style="vertical-align:top"><p>Body as a Whole:</p></td><td style="vertical-align:top"><p>Anaphylaxis/Anaphylactoid</p><p>Reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Perinatal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorder</p><p>Tachycardia Bigeminy Bradycardia</p><p>Premature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ventricular Contractions</p><p>Hemorrhage</p><p>ECG&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal</p><p>Arrhythmia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrial Fever</p><p>Extremities&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain</p><p>Anticholinergic Syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular:</p></td><td style="vertical-align:top"><p>Premature Atrial Contractions</p><p>Syncope</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Central Nervous System:</p></td><td style="vertical-align:top"><p>Hypertonia/Dystonia,</p><p>Paresthesia</p></td><td style="vertical-align:top"><p>Agitation</p></td></tr><tr><td style="vertical-align:top"><p>Digestive:</p></td><td style="vertical-align:top"><p>Hypersalivation</p><p>Nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hemic/Lymphatic:</p></td><td style="vertical-align:top"><p>Leukocytosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection Site:</p></td><td style="vertical-align:top"><p>Phlebitis</p><p>Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic:</p></td><td style="vertical-align:top"><p>Hypomagnesemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal:</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous:</p></td><td style="vertical-align:top"><p>Dizziness Agitation</p><p>Chills</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Somnolence</p><p>Delirium</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory:</p></td><td style="vertical-align:top"><p>Wheezing Cough Laryngospasm</p><p>Hypoxia</p></td><td style="vertical-align:top"><p>Decreased lung infection</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Appendages:</p></td><td style="vertical-align:top"><p>Flushing, Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Special Senses:</p></td><td style="vertical-align:top"><p>Amblyopia</p><p>Vision Abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Urogenital:</p></td><td style="vertical-align:top"><p>Cloudy Urine</p></td><td style="vertical-align:top"><p>Green urine</p></td></tr></tbody></table><p>Incidence less than 1% - Causal Relationship Unknown</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anesthesia/MAC Sedation</p></td><td style="vertical-align:top"><p>ICU Sedation</p></td></tr><tr><td style="vertical-align:top"><p>Body as a Whole:</p></td><td style="vertical-align:top"><p>Asthenia, Awareness, Chest Pain, Extremities Pain, Fever, Increased Drug&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effect,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neck Rigidity/Stiffness,</p><p>Trunk Pain</p></td><td style="vertical-align:top"><p>Fever, Sepsis, Trunk Pain, Whole Body Weakness</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular:</p></td><td style="vertical-align:top"><p>Arrhythmia, Atrial Fibrillation, Atrioventricular Heart Block, Bigeminy, Bleeding, Bundle Branch Block, Cardiac Arrest, ECG</p><p>Abnormal, Edema, Extrasystole, Heart</p><p>Block, Hypertension, Myocardial Infarction, Myocardial Ischemia, Premature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ventricular Contractions,</p><p>ST Segment Depression,</p></td><td style="vertical-align:top"><p>Arrhythmia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrial Fibrillation,</p><p>Bigeminy, Cardiac Arrest, Extrasystole, Right Heart Failure,</p><p>Ventricular Tachycardia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:top"><p>Supraventricular&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tachycardia,</p><p>Tachycardia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ventricular Fibrillation</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Central Nervous System:</p></td><td colspan="2" style="vertical-align:top"><p>Abnormal&nbsp;&nbsp;&nbsp;&nbsp; Dreams,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agitation, Amorous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Behavior,&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, Bucking/Jerking/Thrashing, Chills/Shivering/Clonic/Myoclonic Movement,&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Combativeness, Confusion, Delirium, Depression, Dizziness,&nbsp;&nbsp;&nbsp; Emotional&nbsp;&nbsp;&nbsp;&nbsp; Lability, Euphoria, Fatigue, Hallucinations, Headache,&nbsp;&nbsp; Hypotonia,&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hysteria, Insomnia, Moaning, Neuropathy, Opisthotonos, Rigidity, Seizures,</p><p>Somnolence, Tremor, Twitching</p></td><td colspan="3" style="vertical-align:top"><p>Chills/Shivering, Intracranial Hypertension,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures,</p><p>Somnolence,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thinking Abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Digestive:</p></td><td colspan="2" style="vertical-align:top"><p>Cramping, Diarrhea, Dry Mouth, Enlarged&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Parotid,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea,</p><p>Swallowing,Vomiting</p></td><td style="vertical-align:top"><p>Ileus, Abnormal</p></td><td style="vertical-align:top"><p>Liver</p></td><td style="vertical-align:top"><p>Function</p></td></tr><tr><td style="vertical-align:top"><p>Hematologic/Lymphatic:</p></td><td style="vertical-align:top"><p>Coagulation</p><p>Leukocytosis</p></td><td style="vertical-align:top"><p>Disorder,</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection Site:</p></td><td style="vertical-align:top"><p>Hives/Itching,</p><p>Redness/Discoloration</p></td><td style="vertical-align:top"><p>Phlebitis,</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic/Nutritional:</p></td><td colspan="2" style="vertical-align:top"><p>Hyperkalemia, Hyperlipemia</p></td><td colspan="3" style="vertical-align:top"><p>BUN&nbsp;&nbsp;&nbsp; Increased,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Creatinine Increased,</p><p>Dehydration,</p><p>Hyperglycemia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolic Acidosis,</p><p>Osmolality Increased</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory:</p></td><td colspan="2" style="vertical-align:top"><p>Bronchospasm, Burning in Throat,</p></td><td colspan="3" style="vertical-align:top"><p>Hypoxia</p></td></tr></tbody></table><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Cough, Dyspnea, Hiccough, Hyperventilation, Hypoventilation, Hypoxia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laryngospasm, Pharyngitis,</p><p>Sneezing, Tachypnea, Upper Airway</p><p>Obstruction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Appendages:</p></td><td style="vertical-align:top"><p>Conjunctival&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hyperemia, Diaphoresis,</p><p>Urticaria</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Special Senses:</p></td><td style="vertical-align:top"><p>Diplopia,&nbsp;&nbsp; Ear&nbsp;&nbsp; Pain,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Eye&nbsp;&nbsp; Pain,</p><p>Nystagmus,&nbsp;&nbsp;&nbsp;&nbsp; Taste&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Perversion, Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Urogenital:</p></td><td style="vertical-align:top"><p>Oliguria, Urine Retention</p></td><td style="vertical-align:top"><p>Kidney failure</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p><p><strong>To report any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</p><p>&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>The National Pharmacovigilance and Drug Safety Centre (NPC) </strong></p><p>&nbsp;</p><p>o SFDA Call Center: 19999</p><p>o E-mail: npc.drug@sfda.gov.sa</p><p>o Website: https://ade.sfda.gov.sa/</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Keep out of reach of children.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Store below 30 &deg;C.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Store this medicine in the original package and keep the bottle&nbsp; tightly&nbsp; closed&nbsp; in&nbsp; order&nbsp; to&nbsp; protect from moisture.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp; Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp; What Sefadol contains</p><p>The active substance is Propofol.</p><p>&nbsp;</p><p>Propofol Injectable Emulsion USP 200mg/20mL</p><p><strong>&nbsp;</strong></p><p>Each mL contains 10mg of Propfol USP.</p><p>&nbsp;</p><p>The other ingredients are: Refined soyabean oil, Glycerol Anhydrous, Purified egg yolk lecithin, Edetate disodium, Sodium hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Sefadol looks like?

Propofol Injectable Emulsion USP 200mg/20mL
Milky white to off-white emulsion.
How supplied:

Propofol Injectable Emulsion USP 200mg/20mL
Injections are supplied in 1 Tubular glass Vial.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder Saudi Amarox Industrial Company</p><p>Al Jamiah Street, Al Malaz District Riyadh 12629, Saudi Arabia</p><p>Tel &amp; Fax: +966 11 226 8850</p><p><strong>Manufacturer </strong></p><p>M/s Aspiro Pharma Limited&ndash; India</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Last revised in November 2023, Version 1.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما هو سيدافول:</strong></p><p dir="RTL">سيدافول هو دواء للتخدير العام يستخدم عن طريق الحقن في الوريد وهو أيضا عقار مهدئ يستخدم في تحفيز واستمرار التخدير أو التهدئة. يؤدي حقن سيدافول في الوريد بجرعة علاجية إلى التخدير، مع الحد الأدنى من الإثارة، عادةً في غضون 40 ثانية من بدء الحقن (وقت الدورة الدموية الواحدة الذراع-المخ). كما هو الحال مع عوامل التخدير الوريدية الأخرى سريعة المفعول، فإن نصف الوقت لمعادلة الدم في الدماغ هو حوالي دقيقة واحدة إلى 3 دقائق، وهو ما يمثل معدل تحفيز التخدير. ومثل جميع أدوية التخدير العامة فإن آلية العمل غير مفهومة جيدًا. ومع ذلك، يُعتقد أن سيدافول ينتج آثاره المهدئة / المخدرة من خلال التعديل الإيجابي للوظيفة المثبطة للناقل العصبي GABA من خلال مستقبلات GABAA المترابطة.</p><p dir="RTL">&nbsp;سيدافول هو دواء تخدير عام وريدي يمكن استخدامه كما هو موصوف في الجدول أدناه.</p><p dir="RTL">دواعي استخدام سيدافول</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL">دواعي الاستخدام</p></td><td><p dir="RTL">الفئة العمرية المعتمدة</p></td></tr><tr><td><p dir="RTL">بدء واستمرارية التخدير تحت المراقبة (MAC)</p></td><td><p dir="RTL">البالغين فقط</p></td></tr><tr><td><p dir="RTL">تهدئة مع تخدير موضعي</p></td><td><p dir="RTL">البالغين فقط (أنظر التحذيرات)</p></td></tr><tr><td><p dir="RTL">بدء التخدير العام</p></td><td><p dir="RTL">المرضى أكبر من أو يساوي 3 سنوات من العمر</p></td></tr><tr><td><p dir="RTL">استمرارية التخدير العام</p></td><td><p dir="RTL">المرضى أكبر من أو يساوي شهرين من العمر</p></td></tr><tr><td><p dir="RTL">تهدئة للمرضى الموضوعين على أجهزة التنفس الصناعي داخل وحدة العناية المركزة (ICU)</p></td><td><p dir="RTL">البالغين فقط</p></td></tr></tbody></table><p dir="RTL">لم يتم التحقق من سلامة وفعالية استخدام سيدافول للتهدئة في حالات الأطفال قبل بدء واستمرارية التخدير تحت المراقبة (MAC)؛ لذلك، لا ينصح بالاستخدام في هه الحالة (<u>انظر التحذيرات، استخدام الأطفال</u>).</p><p dir="RTL">سيدافول غير موصى به لتحفيز التخدير في الأطفال تحت سن 3 سنوات أو لمواصلة التخدير تحت سن شهرين لأن سلامته وفعاليته لم تثبت لدى هذه الفئة العمرية.</p><p dir="RTL">يمكن إعطاء سيدافول لتهدئة المرضى الموضوعين على أجهزة التنفس الصناعي داخل وحدة العناية المركزة (ICU)، لتوفير التهدئة والتحكم المستمر في استجابات الإجهاد فقط من قبل الأشخاص المتخصصين في التعامل مع الحالات الطبية للمرضى المصابين بأمراض خطيرة والمدربين على الإنعاش القلبي الوعائي وحالات انسداد مجرى الهواء.</p><p dir="RTL">&nbsp;لم يتم الإشارة إلى استخدام سيدافول في وحدة العناية المركزة للأطفال للتهدئة حيث لم يتم إثبات سلامة هذا (انظر التحذيرات، استخدام الأطفال).</p><p dir="RTL">سيدافول غير موصى به للتوليد، بما في ذلك الولادة القيصرية. حيث أن سيدافول يعبر المشيمة، وكما هو الحال مع أدوية التخدير العام الأخرى، قد تترافق استخدام سيدافول مع اكتئاب حديثي الولادة (انظر التحذيرات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينصح باستخدام سيدافول للأمهات المرضعات لأنه تم الإبلاغ عن إفراز سيدافول في لبن الأم، وتأثيرات الامتصاص الفموي لكميات صغيرة من سيدافول غير معروفة (انظر التحذيرات).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تستخدم سيدافول</strong></p><p dir="RTL">لا يستعمل سيدافول للمرضى الذين لديهم فرط حساسية لمادة سيدافول أو لأي من مكونات سيدافول.</p><p dir="RTL">لا يستعمل سيدافول للمرضى الذين يعانون من الحساسية تجاه البيض أو منتجات البيض أو فول الصويا أو منتجات الصويا.</p><p dir="RTL"><strong>التحذيرات والاحتياطات</strong></p><p dir="RTL">ارتبط استخدام سيدافول مع تفاعلات تأقية وتفاعلات قاتلة ومهددة للحياة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">بالنسبة للتخدير العام أو التهدئة قبل التخدير الخاضع للمراقبة (MAC)، يجب أن يتم إعطاء سيدافول فقط من قبل أشخاص مدربين على التخدير العام وليسوا مشاركين في إجراء الجراحة / إجراء التشخيص. يجب مراقبة المرضى المهدئين بشكل مستمر، ويجب أن تتوفر على الفور وسائل للتغلب على انسداد مجرى الهواء التي قد تحدث، وتوفير التنفس الاصطناعي، وتوفير الأكسجين الإضافي، وإنشاء إنعاش القلب والأوعية الدموية. يجب مراقبة المرضى باستمرار بحثًا عن الأعراض المبكرة لانخفاض ضغط الدم، وانقطاع النفس، وانسداد مجرى الهواء، و / أو تشبع الأكسجين. من المرجح أن تحدث هذه التأثيرات القلبية التنفسية بعد حدوث البلع السريع، خاصة عند كبار السن أو الوهن أو المرضى المصنفين حسب حالات الخطورة إلى (مريض مصاب بمرض جهازي شديد) ASA-PS III أو (مريض بمرض جهازي شديد مهدد للحياة بشكل مستمر) IV.</p><p dir="RTL">&nbsp;بالنسبة إلى استخدام سيدافول لتهدئة المرضى الموضوعين على أجهزة التنفس الصناعي داخل وحدة العناية المركزة (ICU)، يجب أن يتم إعطاء سيدافول فقط من قبل الأشخاص المتخصصين في التعامل مع الحالات الطبية للمرضى المصابين بأمراض خطيرة والمدربين على الإنعاش القلبي الوعائي وحالات انسداد مجرى الهواء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ارتبط استخدام سيدافول لكل من البالغين والأطفال في وحدة العناية المركزة للأطفال للتهدئة مع مجموعة من الاضطرابات الأيضية وفشل بعض الأعضاء، والتي يشار إليها باسم ﻣﺘﻼﺯﻣﺔ&nbsp;ﺗﺪﻓﻖ&nbsp;ﺍﻟﺒﺮﻭﺑﻮﻓﻮﻝ، والتي قد تؤدي إلى الوفاة. تتميز المتلازمة بالحماض الاستقلابي الشديد، فرط بوتاسيوم الدم، شحوم الدم، انحلال الربيدات، تضخم الكبد، الفشل الكلوي، تغيرات تخطيط القلب * و / أو فشل القلب.</p><p dir="RTL">الأعراض التالية هي الأعراض الخطيرة الرئيسية الناتجة عن تطور هذه الأحداث: انخفاض توصيل الأكسجين إلى الأنسجة؛ إصابة عصبية خطيرة و / أو تعفن الدم؛ تناول جرعات عالية من واحد أو أكثر من الأدوية التالية: الأدوية التي تعمل على تضيق الأوعية، المنشطات، مقويات التقلص العضلي و / أو حقن سيدافول بجرعات عالية ولمده طويلة (أكبر من 5 ملجرام / كجم / ساعة لأكثر من 48 ساعة). تم الإبلاغ عن الأعراض أيضًا بعد حقن جرعات كبيرة قصيرة الأمد أثناء التخدير الجراحي. في حالة الحاجة إلى تهدئة مطولة، زيادة جرعة سيدافول للحفاظ على مستوى ثابت من التهدئة، أو بداية الحماض الأيضي أثناء إعطاء حقن سيدافول، ينبغي النظر في استخدام وسائل بديلة للحصول على تهدئة.</p><p dir="RTL">* ارتفاع Coved ST segment (مشابه لتغيرات مخطط كهربية القلب لمتلازمة بروجادا).</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تجنب التوقف المفاجئ عن تناول سيدافول قبل الفطام من التنفس الصناعي أو للتقييم اليومي لمستويات تهدئة. قد يؤدي هذا إلى الاستيقاظ السريع مع القلق، والهياج، ومقاومة التنفس الصناعي. يجب تعديل حقن سيدافول للحفاظ على مستوى خفيف من التهدئة من خلال عملية الفطام من التنفس لصناعي أو تقييم مستوى التهدئة (انظر التحذيرات).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا ينبغي أن يُعطى سيدافول من خلال نفس القسطرة الوريدية بالدم أو البلازما لأنه لم يتم إثبات التوافق. أظهرت الاختبارات في المختبر أنه تتكون تجمعات كروية لتركيبة المستحلب مع الدم / البلازما / المصل من البشر والحيوانات. الأهمية السريرية لهذه النتائج غير معروفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كانت هناك تقارير تفيد بأن الفشل في استخدام تقنية التعقيم عند التعامل مع سيدافول كان مرتبطًا بالتلوث الجرثومي للمنتج والحمى والعدوى والإنتان والأمراض الأخرى التي تهدد الحياة والموت. لا تستخدمه إذا كان هناك شك في وجود تلوث. تجاهل المنتج الدوائي المتبقي وغير المستخدم حسب التوجيهات ضمن الحدود الزمنية المطلوبة (انظر الجرعة وطريقة الاستخدام).</p><p dir="RTL">&nbsp;</p><p dir="RTL">كانت هناك تقارير، في المقالات العلمية والمصادر العامة الأخرى، عن انتقال مسببات الأمراض المنقولة بالدم (مثل التهاب الكبد B، والتهاب الكبد C، وفيروس نقص المناعة البشرية) من ممارسات الحقن غير الآمنة، واستخدام قوارير سيدافول المخصصة للاستخدام الفردي على عدة أشخاص. لذا يجب عدم استخدام قارورة سيدافول أكثر من مرة أو استخدامها لأكثر من شخص واحد.</p><p dir="RTL"><strong>السمية العصبية لدى الأطفال</strong></p><p dir="RTL">تُظهر الدراسات المنشورة على الحيوانات أن إعطاء أدوية التخدير وأدوية التهدئة التي تمنع مستقبلات NMDA و / أو تحفز نشاط GABA تزيد من موت الخلايا المبرمج في الدماغ النامي وتؤدي إلى عجز إدراكي طويل المدى عند استخدامها لمدة تزيد عن 3 ساعات. الأهمية السريرية لهذه النتائج غير واضحة. ومع ذلك، استنادًا إلى البيانات المتاحة، يُعتقد أن نافذة قابلية الإصابة تجاه هذه التغييرات مرتبطة بالاستخدام في الثلث الثالث من الحمل خلال الأشهر العديدة الأولى من العمر، ولكنها قد تمتد إلى ما يقرب من ثلاث سنوات من العمر عند البشر (انظر التحذيرات الوقائية، الحمل، استخدام الأطفال؛ علم السموم الحيوانية و / أو علم الأدوية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">تشير بعض الدراسات المنشورة على الأطفال إلى أن حالات العجز المماثلة قد تحدث بعد التعرض المتكرر أو المطول لعوامل التخدير في وقت مبكر من الحياة وقد تؤدي إلى آثار معرفية أو سلوكية معاكسة. هذه الدراسات لها حدود كبيرة، وليس من الواضح ما إذا كانت الآثار الملحوظة ناتجة عن استخدام أدوية التخدير / التهدئة أو عوامل أخرى مثل الجراحة أو المرض الأساسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تعتبر أدوية التخدير وعقاقير التهدئة جزءًا ضروريًا من رعاية الأطفال الذين يحتاجون إلى جراحة أو إجراءات أخرى أو اختبارات لا يمكن تأخيرها، ولم يتم إثبات أن أي أدوية محددة أكثر أمانًا من أي أدوية أخرى. يجب أن تأخذ القرارات المتعلقة بتوقيت أي إجراءات اختيارية تتطلب التخدير في الاعتبار فوائد الإجراء مقارنة بالمخاطر المحتملة.</p><p dir="RTL"><strong>الاحتياطات:</strong></p><p dir="RTL"><strong>عام</strong></p><p dir="RTL"><strong>المرضى البالغين والأطفال</strong></p><p dir="RTL">في المرضى المسنين أو المنهكين أو فئات ASA-PS III أو IV يجب استخدام أقل جرعة بدء والحقن بمعدل أبطأ (انظر الجرعة والاستخدام). يجب مراقبة المرضى باستمرار بحثًا عن العلامات المبكرة لانخفاض ضغط الدم و / أو بطء القلب. غالبًا ما يحدث انقطاع النفس الذي يتطلب دعمًا للتنفس أثناء التحفيز وقد يستمر لأكثر من 60 ثانية. يتطلب استخدام سيدافول الحذر عند إعطائه للمرضى الذين يعانون من اضطرابات التمثيل الغذائي للدهون مثل فرط شحميات الدم الأولي، فرط شحميات الدم السكري، والتهاب البنكرياس.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرا جدا ما قد يترافق استخدام سيدافول مع تطور فترة من فقدان الوعي بعد العملية الجراحية والتي قد تكون مصحوبة بزيادة في التوتر العضلي. قد يسبق ذلك أو لا يسبقه فترة وجيزة من اليقظة. الانتعاش بشكل عفوي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">عندما يتم إعطاء سيدافول لمريض صرع، هناك خطر حدوث نوبة صرع خلال مرحلة الاستشفاء.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب الانتباه لتقليل الألم عند تناول سيدافول. يمكن تقليل الألم الموضعي العابر إذا تم استخدام الأوردة الكبيرة في الساعد أو الحفرة المرفقية. يمكن أيضًا تقليل الألم أثناء الحقن في الوريد عن طريق الحقن المسبق لليدوكائين IV (1 مل من محلول 1 ٪). يحدث الألم عند الحقن بشكل متكرر في مرضى الأطفال (45 ٪) عندما تم استخدام وريد صغير في اليد دون الاستخدام المسبق لليدوكائين. مع الاستخدام المسبق لليدوكائين أو عند استخدام الأوردة المضادة للالتهاب، كان الألم ضئيلًا (حدوث أقل من 10 ٪) ويمكن تحمله. كانت هناك تقارير في المقالات العلمية تشير إلى أن إضافة ليدوكائين إلى سيدافول بكميات أكبر من 20 ملجرام ليدوكائين / 200 ملجرام سيدافول ينتج عنه عدم استقرار المستحلب المرتبط بزيادة أحجام الكريات بمرور الوقت (في دراسات على الفئران) وانخفاض في فعالية التخدير. لذلك، يوصى بإعطاء ليدوكائين قبل إعطاء سيدافول أو إضافته إلى سيدافول مباشرة قبل الإعطاء وبكميات لا تتجاوز 20 ملجرام ليدوكائين / 200 ملجرام سيدافول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تم الإبلاغ عن التبعيات الوريدية، مثل التهاب الوريد أو الجلطة، نادرًا (أقل من 1 ٪). في دراستين سريريتين باستخدام القسطرة الوريدية المخصصة، لم يلاحظ أي حالات من العواقب الوريدية حتى 14 يومًا بعد الاستخدام.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحقن داخل الشرايين في الحيوانات لا يسبب تأثيرات على الأنسجة الموضعية. تم الإبلاغ عن الحقن العرضي داخل الشرايين في المرضى، وبخلاف الألم، لم تكن هناك مضاعفات مرضية كبيرة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تسبب الحقن المتعمد في أنسجة الحيوانات تحت الجلد أو حول الأوعية الدموية في تفاعلات محدودة بالأنسجة. خلال فترة ما بعد التسويق، كانت هناك تقارير نادرة عن ألم موضعي، وتورم، و / أو بثور، و / أو نخر الأنسجة بعد التسرب العرضي لسيدافول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحدث الرمع العضلي المحيط بالجراحة، والذي نادرًا ما يتضمن التشنجات والتشنج الظهري، بالاشتراك مع استخدام سيدافول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادراً ما تحدث المظاهر السريرية للتأق، بما في ذلك الوذمة الوعائية والتشنج القصبي والحمامي وانخفاض ضغط الدم، بعد تناول سيدافول.</p><p dir="RTL">&nbsp;</p><p dir="RTL">كانت هناك تقارير نادرة عن الوذمة الرئوية بشكل مؤقت مع إعطاء سيدافول، على الرغم من أن العلاقة السببية غير معروفة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نادرًا ما تم الإبلاغ عن حالات التهاب البنكرياس غير المبرر بعد الجراحة (التي تتطلب دخول المستشفى) بعد التخدير الذي كان فيه سيدافول أحد عوامل التحفيز المستخدمة. بسبب مجموعة متنوعة من العوامل المحيرة في هذه الحالات، بما في ذلك الأدوية المصاحبة، فإن العلاقة السببية مع سيدافول غير واضحة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ليس لسيدافول أي نشاط مبهم. ارتبطت تقارير بطء القلب وانقباض القلب والسكتة القلبية لسيدافول. مرضى الأطفال معرضون لهذا التأثير، خاصة عند إعطاء الفنتانيل بشكل متزامن. ينبغي النظر في إعطاء الوريد لعوامل مضادات الكولين (على سبيل المثال، الأتروريين أو الجليكوبيرولات) لتعديل الزيادات المحتملة في نمط العصب الحائر بسبب العوامل المصاحبة (على سبيل المثال، السكسينيل كولين) أو المنبهات الجراحية.</p><p dir="RTL"><strong>الأدوية الأخرى وسيدافول</strong></p><p dir="RTL">قد يتم تقليل الجرعة التحفيزية من سيدافول وذلك في المرضى الذين يعانون من التخدير العضلي أو الوريدي، خاصةً مع الأدوية المخدرة (مثل المورفين والميبيريدين والفنتانيل، إلخ) وتوليفات المواد الأفيونية والمهدئات (على سبيل المثال، البنزوديازيبينات، الباربيتورات، الكلورال هيدرات، الدروبيريدول، إلخ.). قد تزيد هذه العوامل من التأثيرات المخدرة أو المهدئة لسيدافول وقد تؤدي أيضًا إلى انخفاض أكثر وضوحًا في الضغط الشرياني الانقباضي والانبساطي والمتوسط والناتج القلبي.</p><p dir="RTL">أثناء مرحلة المداومة على التخدير أو التهدئة، يجب تعديل معدل إعطاء سيدافول وفقًا لمستوى التخدير أو التهدئة المطلوب ويمكن تقليله في وجود عوامل مسكنة تكميلية (مثل أكسيد النيتروز أو المواد الأفيونية). لم يتم تقييم الاستخدام المتزامن لعوامل الاستنشاق القوية (مثل ايزوفلورن وانفلوران وهالوثان) أثناء مرحلة المداومة مع سيدافول على نطاق واسع. يمكن أن نتوقع أيضًا أن تزيد عوامل الاستنشاق هذه من التأثيرات المخدرة أو المهدئة والقلبية التنفسية لسيدافول.</p><p dir="RTL">قد يؤدي الاستخدام المتزامن لفالبروات وسيدافول إلى زيادة مستويات سيدافول في الدم. يجب تقليل جرعة سيدافول عند المشاركة مع فالبروات. راقب المرضى عن كثب بحثًا عن علامات زيادة تهدئة أو اكتئاب قلبي تنفسي.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يتسبب سيدافول في حدوث تغيير مهم سريريًا في بداية أو شدة أو مدة تأثير عوامل الحجب العصبي العضلي الشائعة الاستخدام (على سبيل المثال، السكسينيل كولين ومرخيات العضلات غير الاستقطابية).</p><p dir="RTL">&nbsp;</p><p dir="RTL">لم تلاحظ أي تفاعلات سلبية كبيرة مع الأدوية الأولية أو الأدوية المستخدمة أثناء التخدير أو تهدئة (بما في ذلك مجموعة من مرخيات العضلات وعوامل الاستنشاق والعوامل المسكنة وعوامل التخدير الموضعي) عند البالغين. في مرضى الأطفال، قد يؤدي إعطاء الفنتانيل بالتزامن مع سيدافول إلى بطء خطير بالقلب.</p><p dir="RTL"><strong>ضعف الخصوبة</strong></p><p dir="RTL">تم حقن سيدافول في إناث فئران ويستار عن طريق الوريد إما 0 أو 10 أو 15 ملجرام / كغم / يوم قبل الحمل بأسبوعين إلى اليوم السابع من الحمل لم تظهر ضعف الخصوبة (0.65 و1 مرة قدر الجرعة التحفيزية للإنسان 2.5 ملجرام / كغم على أساس مساحة سطح الجسم). لم تتأثر خصوبة الذكور في الجرذان في دراسة مميتة سائدة بجرعات وريدية تصل إلى 15 ملجرام / كغم / يوم لمدة 5 أيام.</p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL"><strong>ملخص المخاطر</strong></p><p dir="RTL">لا توجد دراسات كافية ومحكمة جيدًا عند النساء الحوامل. في دراسات التكاثر الحيواني، لوحظ انخفاض بقاء الجراء على قيد الحياة متزامنًا مع زيادة معدل وفيات الأمهات عند إعطاء سيدافول في الوريد للفئران الحوامل إما قبل التزاوج وأثناء الحمل المبكر أو أثناء الحمل المتأخر والرضاعة المبكرة عند تعرضها لجرعة سيدافول في الوريد أقل من الجرعة التحفيزية للإنسان البالغة 2.5 ملجرام / كغم. في الجرذان الحامل التي تم إعطاؤها جرعة سيدافول في الوريد 15 ملجرام / كغم / يوم (ما يعادل الجرعة الاستمرارية البشرية) وذلك قبل التزاوج بأسبوعين إلى بداية الحمل (يوم الحمل 7)، كان النسل الذي سُمح له بالتزاوج قد زاد من خسائر ما بعد الزرع. من المحتمل أن يكون النشاط الدوائي (التخدير) للدواء على الأم هو المسؤول عن الآثار الضارة التي تظهر في النسل.</p><p dir="RTL">تُظهر الدراسات المنشورة في الأمهات الحوامل أن إعطاء الأدوية المخدرة وعقاقير التهدئة التي تمنع مستقبلات NMDA و / أو تحفز نشاط GABA خلال فترة ذروة نمو الدماغ يزيد من موت الخلايا المبرمج في الدماغ النامي للنسل عند استخدامه لمدة تزيد عن 3 ساعات. لا توجد بيانات عن حالات التعرض للحمل في الأمهات المقابلة للفترات السابقة للثلث الثالث من الحمل عند البشر [انظر البيانات].</p><p dir="RTL">المخاطر الخلفية المقدرة للعيوب الخلقية الرئيسية والإجهاض للفئة العمرية المشار إليها غير معروفة. جميع حالات الحمل لها مخاطر أساسية تتمثل في حدوث عيوب خلقية أو فقدان أو نتائج سلبية أخرى. في عموم السكان في الولايات المتحدة، تبلغ المخاطر الخلفية المقدرة للعيوب الخلقية الرئيسية والإجهاض في حالات الحمل المعترف بها سريريًا 2-4٪ و15-20٪ على التوالي.</p><p dir="RTL"><strong>ا</strong><strong>لتوليد، بما في ذلك الولادات القيصرية</strong></p><p dir="RTL">سيدافول لا ينصح به للتوليد، بما في ذلك الولادات القيصرية. سيدافول يعبر المشيمة، وكما هو الحال مع عوامل التخدير العام الأخرى، فإن إعطاء سيدافول قد يترافق مع اكتئاب حديثي الولادة.</p><p dir="RTL"><strong>الأمهات المرضعات</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">لا يُنصح باستخدام سيدافول في المرضعات لأنه تم الإبلاغ عن إفراز سيدافول في لبن الأم، كما أن تأثيرات الامتصاص الفموي لكميات صغيرة من سيدافول غير معروفة.</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">يجب إخطار المرضى بأن أداء الأنشطة التي تتطلب اليقظة العقلية، مثل تشغيل السيارات أو الآلات الخطرة أو التوقيع على المستندات القانونية قد يتضرر لبعض الوقت بعد التخدير العام أو تهدئة.</p><p dir="RTL"><strong>تأثير أدوية التخدير والتهدئة على نمو الدماغ المبكر</strong></p><p dir="RTL">تشير الدراسات التي أجريت على الحيوانات الصغيرة والأطفال إلى أن الاستخدام المتكرر أو المطول للتخدير العام أو أدوية التهدئة في الأطفال الذين تقل أعمارهم عن 3 سنوات قد يكون لها آثار سلبية على نمو أدمغتهم. ناقش مع الوالدين ومقدمي الرعاية الفوائد والمخاطر وتوقيت ومدة الجراحة أو الإجراءات التي تتطلب التخدير وأدوية تهدئة (انظر التحذيرات، السمية العصبية للأطفال).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تتناسب تركيزات سيدافول في الدم وذلك في الحالة المستقرة بشكل عام مع معدلات التسريب، خاصة في المرضى الأفراد. من المحتمل أن تحدث تأثيرات غير مرغوب فيها مثل الاكتئاب القلبي التنفسي في تركيزات الدم المرتفعة والتي تنتج عن جرعات البلعة أو الزيادات السريعة في معدل التسريب. يجب السماح بفترة كافية بين تعديلات الجرعة (3 دقائق إلى 5 دقائق) للسماح وتقييم الآثار السريرية.</p><p dir="RTL">يجب رج العبوة جيداً قبل الاستخدام. لا تستخدمه إذا كان هناك دليل على تحول المستحلب إلى شكل الكريمات أو تكون ترسيبات، أو إذا كانت هناك قطرات كبيرة مرئية، أو إذا كانت هناك أشكال أخرى لفصل مكونات المستحلب تشير إلى تعرض ثبات المنتج للخطر. قد يحدث تحول المستحلب إلى شكل الكريمات بنسبة بسيطة بسبب التخزين والذي يجب أن يختفي بعد الرج.</p><p dir="RTL">عند استخدام سيدافول عن طريق التسريب، يوصى باستخدام الحقن أو المضخات القياسية لتوفير معدلات تسريب مضبوطة. عند حقن سيدافول للمرضى الذين يخضعون للتصوير بالرنين المغناطيسي، يمكن استخدام أجهزة التحكم المدرجة إذا كانت المضخات الميكانيكية غير عملية.</p><p dir="RTL">قد تحدث تغيرات في العلامات الحيوية التي تشير إلى الاستجابة للتحفيز الجراحي أو الخروج من التخدير عن طريق إعطاء 25 ملجرام (2.5 مل) إلى 50 ملجرام (5 مل) بلعات إضافية و / أو عن طريق زيادة معدل ضخ سيدافول.</p><p dir="RTL">بالنسبة للإجراءات الجراحية البسيطة (على سبيل المثال، سطح الجسم) يمكن دمج أكسيد النيتروز (60٪ إلى 70٪) مع تسريب سيدافول بمعدل متغير لتوفير تخدير مناسب. مع المزيد من الإجراءات الجراحية المحفزة (على سبيل المثال، داخل البطن)، أو إذا لم يتم توفير مكملات بأكسيد النيتروز، يجب زيادة معدل (معدلات) حقن سيدافول و / أو المواد الأفيونية من أجل توفير التخدير المناسب.</p><p dir="RTL">يجب دائمًا معايرة معدلات التسريب نزوليًا في حالة عدم وجود علامات سريرية للتخدير الخفيف حتى يتم الحصول على استجابة خفيفة للتحفيز الجراحي من أجل تجنب إعطاء سيدافول بمعدلات أعلى مما هو ضروري سريريًا. بشكل عام، يجب تحقيق معدلات من 50 ميكروغرام / كغم / دقيقة إلى 100 ميكروغرام / كغم / دقيقة عند البالغين أثناء جرعة الاستمرارية من أجل تحسين أوقات الاستفاقة.</p><p dir="RTL">يمكن للأدوية الأخرى التي تسبب تثبيط الجهاز العصبي المركزي (مثل المهدئات والمخدرات والمواد الأفيونية) أن تزيد من تثبيط الجهاز العصبي المركزي الناجم عن سيدافول. ثبت أن المورفين (0.15 ملجرام / كلغم) مع أكسيد النيتروز بنسبة 67 ٪ في الأكسجين يقلل من معدل التسريب اللازم لصيانة حقن سيدافول وتركيزات الدم العلاجية عند مقارنته بالتخدير غير المخدر (لورازيبام).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">معلومات الآثار الجانبية المحتملة مستمدة من التجارب السريرية الخاضعة للرقابة والخبرة التسويقية العالمية. في الوصف أدناه، تمثل معدلات الآثار الجانبية الأكثر شيوعًا نتائج الدراسات السريرية الأمريكية / الكندية. كما تُستمد الآثار الجانبية الأقل تواتراً من المنشورات وخبرات التسويق لدى أكثر من 8 ملايين مريض؛ لا توجد بيانات كافية لدعم تقدير دقيق لمعدلات حدوثها. أجريت هذه الدراسات باستخدام مجموعة متنوعة من أدوية ما قبل التخدير، وفترات متفاوتة من الإجراءات الجراحية / التشخيصية، والعديد من عوامل التخدير / المسكنات الأخرى. كانت معظم الآثار الجانبية خفيفة وعابرة.</p><p dir="RTL"><strong>بدء واستمرارية التخدير والتهدئة تحت المراقبة </strong><strong>(MAC)</strong><strong> عند البالغين</strong></p><p dir="RTL">تشمل التقديرات التالية للآثار الجانبية لاستخدام سيدافول بيانات من التجارب السريرية في التخدير والتهدئة تحت المراقبة (MAC) (N = 2889 مريضًا بالغًا). الآثار الجانبية المذكورة أدناه والتي من المحتمل أن تكون مرتبطة سببيًا هي تلك الأحداث التي كان فيها معدل الإصابة الفعلي في المرضى الذين عولجوا باستخدام سيدافول أكبر من معدل حدوث المقارنة في هذه التجارب. لذلك، فإن معدلات حدوث الآثار الجانبية في التخدير والتهدئة تحت المراقبة (MAC) عند البالغين تمثل عمومًا تقديرات النسبة المئوية لمرضى التجارب السريرية التي يبدو أن لديهم علاقة سببية محتملة.</p><p dir="RTL">إن ملف الآثار الجانبية من تقارير 150 مريضًا في التجارب السريرية للتخدير والتهدئة تحت المراقبة (MAC) مشابه للملف الشخصي الذي تم إنشاؤه مع سيدافول أثناء التخدير (انظر أدناه). خلال التجارب السريرية للتخدير والتهدئة تحت المراقبة (MAC)، شملت الأحداث التنفسية الهامة السعال وانسداد مجرى الهواء العلوي وانقطاع النفس ونقص التنفس وضيق التنفس.</p><p dir="RTL"><strong>التخدير عند مرضى الأطفال</strong></p><p dir="RTL">بشكل عام، فإن ملف الآثار الجانبية لسيدافول من تقارير 506 من مرضى الأطفال من 6 أيام إلى 16 عامًا في التجارب السريرية للتخدير الأمريكي / الكندي مشابه للملف الشخصي الذي تم إنشاؤه باستخدام سيدافول أثناء التخدير عند البالغين (انظر النسب المئوية للأطفال [الأطفال: ٪] أدناه). على الرغم من عدم الإبلاغ عنه كحدث ضار في التجارب السريرية، إلا أنه كثيرًا ما يلاحظ انقطاع النفس عند مرضى الأطفال.</p><p dir="RTL"><strong>التهدئة داخل وحدة العناية المركزة في البالغين</strong></p><p dir="RTL">تشمل التقديرات التالية للآثار الجانبية بيانات من التجارب السريرية في التهدئة داخل وحدة العناية المركزة (عدد = 159 مريضًا بالغًا). ربما تم تحديد معدلات الإصابة ذات الصلة بالتهدئة داخل وحدة العناية المركزة من خلال مراجعة نموذج تقرير الحالة الفردية. استندت السببية المحتملة إلى علاقة استجابة الجرعة الظاهرة و / أو الاستجابات الإيجابية لإعادة التحدي. في كثير من الحالات، أدى وجود المرض المصاحب والعلاج المصاحب إلى جعل العلاقة السببية غير معروفة. لذلك، معدلات الإصابة لحالات التهدئة داخل وحدة العناية المركزة تمثل عمومًا تقديرات النسبة المئوية لمرضى التجارب السريرية التي يبدو أن لديهم علاقة سببية محتملة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">نسبة الإصابة أكبر من 1٪ - من المحتمل أن تكون ذات صلة سببية</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">بدء واستمرارية التخدير والتهدئة تحت المراقبة (MAC)</p></td><td style="vertical-align:top"><p dir="RTL">التهدئة داخل وحدة العناية المركزة</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p dir="RTL">القلب والأوعية الدموية:</p></td><td style="vertical-align:top"><p dir="RTL">بطء القلب</p></td><td rowspan="5" style="vertical-align:top"><p dir="RTL">بطء القلب</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">قلة النتاج القلبي</p><p dir="RTL">انخفاض ضغط الدم 26٪</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">عدم انتظام ضربات القلب [الأطفال: 1.2٪]</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تسرع&nbsp;القلب العقدي [الأطفال: 1.6٪]</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">انخفاض ضغط الدم * [الأطفال: 17٪] (انظر أيضًا السريرية علم العقاقير)</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">ارتفاع ضغط الدم [الأطفال: 8٪]</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجهاز العصبي المركزي:</p></td><td style="vertical-align:top"><p dir="RTL">حركة * [الأطفال: 17٪]</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">موقع الحقن:</p></td><td style="vertical-align:top"><p dir="RTL">حرقة / لاذع أو وجع 17.6٪ [الأطفال: 10٪]</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">التمثيل الغذائي:</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">فرط شحميات الدم *</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تنفسي:</p></td><td style="vertical-align:top"><p dir="RTL">انقطاع النفس (انظر أيضا الصيدلة السريرية)</p></td><td style="vertical-align:top"><p dir="RTL">الحماض التنفسي أثناء الفطام من التنفس الصناعي *</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجلد والملاحق:</p></td><td style="vertical-align:top"><p dir="RTL">الطفح الجلدي [الأطفال:</p><p dir="RTL">حكة [الأطفال: 2٪]</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr></tbody></table><p dir="RTL">الآثار الجانبية التي لا تحتوي على * أو٪ كانت نسبة حدوثها من 1٪ إلى 3٪</p><p dir="RTL">* نسبة حدوث الآثار الجانبية من 3٪ إلى 10٪</p><p dir="RTL">نسبة الإصابة أقل من 1٪ - من المحتمل أن تكون ذات صلة سببية</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td><td style="vertical-align:top"><p dir="RTL">بدء واستمرارية التخدير والتهدئة تحت المراقبة (MAC)</p></td><td style="vertical-align:top"><p dir="RTL">التهدئة داخل وحدة العناية المركزة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجسد ككل:</p></td><td style="vertical-align:top"><p dir="RTL">تفاعلات الحساسية المفرطة / التأق</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">القلب والأوعية الدموية:</p></td><td style="vertical-align:top"><p dir="RTL">اضطرابات الفترة المحيطة بالولادة</p><p dir="RTL">عدم انتظام دقات القلب</p><p dir="RTL">&nbsp;النبض التوأمي (Bigeminy)</p><p dir="RTL">بطء القلب</p><p dir="RTL">انقباضات سابق لأوانها بالبطين</p><p dir="RTL">نزف</p><p dir="RTL">ECG غير طبيعي</p><p dir="RTL">الحمى الأذينية</p><p dir="RTL">عدم انتظام ضربات القلب</p><p dir="RTL">ألم الأطراف</p><p dir="RTL">متلازمة مضادات الكولين</p><p dir="RTL">الانقباضات الأذينية المبكرة</p><p dir="RTL">إغماء</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجهاز العصبي المركزي:</p></td><td style="vertical-align:top"><p dir="RTL">ارتفاع ضغط الدم / خلل التوتر العضلي،</p><p dir="RTL">تنمل</p></td><td style="vertical-align:top"><p dir="RTL">رعشة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجهاز الهضمي:</p></td><td style="vertical-align:top"><p dir="RTL">زيادة اللعاب</p><p dir="RTL">غثيان</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الدم / ليمفاوية:</p></td><td style="vertical-align:top"><p dir="RTL">زيادة عدد الكريات البيضاء</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">موقع الحقن:</p></td><td style="vertical-align:top"><p dir="RTL">الالتهاب الوريدي</p><p dir="RTL">حكة</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الأيض:</p></td><td style="vertical-align:top"><p dir="RTL">نقص ماغنسيوم الدم</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجهاز العضلي الهيكلي:</p></td><td style="vertical-align:top"><p dir="RTL">ألم عضلي</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجهاز العصبي:</p></td><td style="vertical-align:top"><p dir="RTL">دوار، هياج</p><p dir="RTL">قشعريرة</p><p dir="RTL">نعاس</p><p dir="RTL">هذيان</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">تنفسي:</p></td><td style="vertical-align:top"><p dir="RTL">السعال الصفير تشنج الحنجرة</p><p dir="RTL">نقص الأكسجة</p></td><td style="vertical-align:top"><p dir="RTL">قلة عدوى الرئة</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجلد والأطراف:</p></td><td style="vertical-align:top"><p dir="RTL">احمرار، حكة</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الحواس المميزة:</p></td><td style="vertical-align:top"><p dir="RTL">الحول</p><p dir="RTL">الرؤية غير طبيعية</p></td><td style="vertical-align:top"><p dir="RTL">&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p dir="RTL">الجهاز البولي التناسلي:</p></td><td style="vertical-align:top"><p dir="RTL">بول غائم</p></td><td style="vertical-align:top"><p dir="RTL">بول أخضر</p></td></tr></tbody></table><p dir="RTL">نسبة الإصابة أقل من 1٪ - العلاقة السببية غير معروفة</p><table dir="rtl" border="1" cellspacing="0" cellpadding="0"><tbody><tr><td><p dir="RTL">&nbsp;</p></td><td><p dir="RTL">بدء واستمرارية التخدير والتهدئة تحت المراقبة (MAC)</p></td><td><p dir="RTL">التهدئة داخل وحدة العناية المركزة</p></td></tr><tr><td><p dir="RTL">الجسد ككل:</p></td><td><p dir="RTL">الوهن، ومشاكل بالوعي، وآلام الصدر، وآلام الأطراف، والحمى، وزيادة تأثير الأدوية، وتصلب العنق، وآلام الجذع</p></td><td><p dir="RTL">حمى، تعفن الدم، آلام في الجذع، ضعف في الجسم كله</p><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">القلب والأوعية الدموية:</p></td><td><p dir="RTL">عدم انتظام ضربات القلب، الرجفان الأذيني، إحصار القلب الأذينية البطينية، التورمات الصغيرة، النزيف، احصار الحزيمة، توقف القلب، تخطيط القلب غير طبيعي، وذمة، وانقباض، وانسداد القلب، ارتفاع ضغط الدم، احتشاء عضلة القلب، نقص تروية عضلة القلب، الانقباضات البطينية المبكرة، انخفاض مقطع ST، تسرع القلب فوق البطيني، تسرع القلب والرجفان البطيني</p></td><td><p dir="RTL">الرجفان الأذيني، الانقباضات البطينية المبكرة، السكتة القلبية، انقباض زائد، قصور القلب الأيمن، عدم انتظام دقات القلب البطيني</p></td></tr><tr><td><p dir="RTL">الجهاز العصبي المركزي:</p></td><td><p dir="RTL">أحلام غير طبيعية، هياج، سلوك غرامي، قلق، رعشة / اهتزاز / جلطة، قشعريرة / ارتعاش / حركة رمعية، قتالية، ارتباك، هذيان، اكتئاب، دوار، ضعف عاطفي، ابتهاج، إرهاق، هلوسة، صداع، نقص التوتر، هستيريا، أرق، تئن، اعتلال عصبي، التشنج الظهري، صلابة، نوبات، نعاس، رعشة، ارتعاش</p></td><td><p dir="RTL">قشعريرة / ارتعاش، ارتفاع ضغط الدم داخل الجمجمة، نوبات، نعاس، تفكير غير طبيعي</p></td></tr><tr><td><p dir="RTL">الجهاز الهضمي:</p></td><td><p dir="RTL">المغص، الإسهال، جفاف الفم، تضخم الغدة النكفية، الغثيان، مشاكل البلع، القيء</p></td><td><p dir="RTL">العلوص، الكبد غير الطبيعي</p></td></tr><tr><td><p dir="RTL">الدم / ليمفاوية:</p></td><td><p dir="RTL">اضطراب تجلط الدم</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">موقع الحقن:</p></td><td><p dir="RTL">شرى / حكة، احمرار / تلون وريدي،</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">الأيض:</p></td><td><p dir="RTL">فرط بوتاسيوم الدم، فرط شحميات الدم</p></td><td><p dir="RTL">زيادة نيتروجين اليوريا في الدم BUN، زيادة الكرياتينين،</p><p dir="RTL">الجفاف، ارتفاع السكر في الدم، الحماض الأيضي، زيادة الأسمولية</p></td></tr><tr><td><p dir="RTL">تنفسي:</p></td><td><p dir="RTL">تشنج قصبي، وحرق في الحلق، وسعال، وضيق في التنفس، كحة مرتفعة، وفرط التنفس، ونقص التهوية، ونقص الأكسجة، وتشنج الحنجرة، والتهاب البلعوم، والعطس، وسرعة التنفس، وانسداد مجرى الهواء العلوي</p></td><td><p dir="RTL">نقص الأكسجة</p></td></tr><tr><td><p dir="RTL">الجلد والأطراف:</p></td><td><p dir="RTL">فرط الملتحمة، تعرق، الشرى</p></td><td><p dir="RTL">طفح جلدي</p></td></tr><tr><td><p dir="RTL">الحواس المميزة:</p></td><td><p dir="RTL">الرؤية المزدوجة، آلام في الأذن، آلام في العين، رأرأة، طعم الشذوذ، طنين الأذن</p></td><td><p dir="RTL">&nbsp;</p></td></tr><tr><td><p dir="RTL">الجهاز البولي التناسلي:</p></td><td><p dir="RTL">قلة البول واحتباس البول</p></td><td><p dir="RTL">فشل كلوي</p></td></tr></tbody></table><p><strong>الإبلاغ عن الآثار الجانبية: </strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو مقدم الرعاية الصحية أو الصيدلي.</p><p dir="RTL"><strong>للإبلاغ حول الأعراض الجانبية التي قد تحدث يرجى التواصل عبر العناوين التالية</strong><strong>:</strong></p><ul><li dir="RTL"><strong>المملكة العربية السعودية</strong><strong>:</strong></li></ul><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p dir="RTL">&nbsp;</p><p dir="RTL">&bull; المركز الوطني للتيقظ الدوائي والسلامة الدوائية</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">الموقع الإلكتروني: https://ade.sfda.gov.sa</p><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><ul><br /><li dir="RTL"><strong>دول الخليج العربي الأخرى</strong><strong>:</strong></li></ul><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p><strong>الرجاء</strong><strong> </strong><strong>الاتصال</strong><strong> </strong><strong>بالجهات</strong><strong> </strong><strong>الوطنية</strong><strong> </strong><strong>في</strong><strong> </strong><strong>كل</strong><strong> </strong><strong>دولة</strong></p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احفظ هذا الدواء بعيدًا عن رؤية ومتناول أيدي الأطفال.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب تخزين هذا الدواء في العبوة الأصلية واحتفظ بالزجاجة مغلقة بإحكام من أجل الحماية من الرطوبة.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على العبوة بعد EXP. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر.</p><p dir="RTL">&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تتخلص من الأدوية في مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد بحاجة إليها. ستساعد هذه الإجراءات في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">المادة الفعالة هي بروبوفول</p><p dir="RTL"><strong>مستحلب&nbsp;البروبوفول المتوافق مع دستور الأدوية الأمريكي 200 ملجرام / 20 مل</strong></p><p dir="RTL">يحتوي كل مل على 10 ملجرام بروبوفول المتوافق مع دستور الأدوية الأمريكي</p><p dir="RTL">الصواغات الأخرى هي: زيت الصويا المكرر، الجلسرين اللامائي، ليسيثين صفار البيض المنقى، إيديتات ثنائي الصوديوم، هيدروكسيد الصوديوم وماء للحقن.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ما هو شكل سيدافول؟</strong></p><p dir="RTL"><strong>مستحلب&nbsp;البروبوفول المتوافق مع دستور الأدوية الأمريكي 200 ملجرام / 20 مل</strong></p><p dir="RTL">مستحلب حليبي أبيض إلى أبيض مصفر.</p><p dir="RTL"><strong>كيفية توفير سيدافول؟</strong></p><p dir="RTL"><strong>مستحلب&nbsp;البروبوفول المتوافق مع دستور الأدوية الأمريكي 200 ملجرام / 20 مل</strong></p><p dir="RTL">يتم توفير الحقن في 1 قارورة زجاجية أنبوبية الشكل.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;</strong></p><p><strong>صاحب حق التسويق: اسم وعنوان مالك رخصة التسويق والمصنع</strong><strong> </strong></p><p dir="RTL"><strong>صاحب حق التسويق</strong><strong>:</strong></p><p><strong>شركة أماروكس السعودية للصناعة</strong></p><p>شارع الجامعة ، حي الملز</p><p>الرياض 12629 ، المملكة العربية السعودية</p><p>هاتف و فاكس: 966112268850+</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>المصنع</strong><strong>: </strong></p><p dir="RTL">شركة أسبيرو فارما المحدودة، الهند</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في نوفمبر 2023 ، نسخة 1 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sedafol Injectable Emulsion USP 200mg/20mL
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                200mg/20mL
Each mL contains 10mg of Propofol USP.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Emulsion for injection
Propofol Injectable Emulsion USP 200mg/20mL Milky white to off-white emulsion.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>PROPOFOL is an IV general anesthetic and sedation drug that can be used as described in the table below.</p><p>Indications for PROPOFOL</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Indication</strong></p></td><td style="vertical-align:top"><p><strong>Approved patient population</strong></p></td></tr><tr><td style="vertical-align:top"><p>Initiation and maintenance of Monitored</p><p>Anesthesia Care (MAC) sedation</p></td><td style="vertical-align:top"><p>Adults only</p></td></tr><tr><td style="vertical-align:top"><p>Combined sedation and regional anesthesia</p></td><td style="vertical-align:top"><p>Adults only (see PRECAUTIONS)</p></td></tr><tr><td style="vertical-align:top"><p>Induction of General Anesthesia</p></td><td style="vertical-align:top"><p>Patients greater than or equal to 3 years of</p><p>age</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of General Anesthesia</p></td><td style="vertical-align:top"><p>Patients greater than or equal to 2 months of</p><p>age</p></td></tr><tr><td style="vertical-align:top"><p>Intensive Care Unit (ICU) sedation of</p><p>intubated, mechanically ventilated patients</p></td><td style="vertical-align:top"><p>Adults only</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>Safety, effectiveness and dosing guidelines for PROPOFOL have not been established for MAC Sedation in the pediatric population; therefore, it is not recommended for this use (see <u>PRECAUTIONS</u>, <u>Pediatric Use</u>).</p><p>&nbsp;</p><p>PROPOFOL is not recommended for induction of anesthesia below the age of 3 years or for maintenance of anesthesia below the age of 2 months because its safety and effectiveness have not been established in those populations.</p><p>&nbsp;</p><p>In the Intensive Care Unit (ICU), PROPOFOL can be administered to intubated, mechanically ventilated adult patients to provide continuous sedation and control of stress responses only by persons skilled in the medical management of critically ill patients and trained in cardiovascular resuscitation and airway management.</p><p>&nbsp;</p><p>PROPOFOL is not indicated for use in Pediatric ICU sedation since the safety of this regimen has not been established (see <u>PRECAUTIONS</u>, <u>Pediatric Use</u>).</p><p>&nbsp;</p><p>PROPOFOL is not recommended for obstetrics, including Cesarean section deliveries. PROPOFOL crosses the placenta, and as with other general anesthetic agents, the administration of PROPOFOL may be associated with neonatal depression (see <u>PRECAUTIONS</u>).</p><p>&nbsp;</p><p>PROPOFOL is not recommended for use in nursing mothers because Propofol has been reported to be excreted in human milk, and the effects of oral absorption of small amounts of Propofol are not known (see <u>PRECAUTIONS</u>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Propofol blood concentrations at steady-state are generally proportional to infusion rates, especially in individual patients. Undesirable effects such as cardiorespiratory depression are likely to occur at higher blood concentrations which result from bolus dosing or rapid increases in the infusion rate. An adequate interval (3 minutes to 5 minutes) must be allowed between dose adjustments to allow for and assess the clinical effects.</p><p>&nbsp;</p><p>Shake well before use. Do not use if there is evidence of excessive creaming or aggregation, if large droplets are visible, or if there are other forms of phase separation indicating that the stability of the product has been compromised. Slight creaming, which should disappear after shaking, may be visible upon prolonged standing.</p><p>&nbsp;</p><p>When administering PROPOFOL by infusion, syringe or volumetric pumps are recommended to provide controlled infusion rates. When infusing PROPOFOL to patients undergoing magnetic resonance imaging, metered control devices may be utilized if mechanical pumps are impractical.</p><p>&nbsp;</p><p>Changes in vital signs indicating a stress response to surgical stimulation or the emergence from anesthesia may be controlled by the administration of 25 mg (2.5 mL) to 50 mg (5 mL) incremental boluses and/or by increasing the infusion rate of PROPOFOL.</p><p>&nbsp;</p><p>For minor surgical procedures (e.g., body surface) nitrous oxide (60% to 70%) can be combined with a variable rate PROPOFOL infusion to provide satisfactory anesthesia. With more stimulating surgical procedures (e.g., intra-abdominal), or if supplementation with nitrous oxide is not provided, administration rate(s) of PROPOFOL and/or opioids should be increased in order to provide adequate anesthesia.</p><p>&nbsp;</p><p>Infusion rates should always be titrated downward in the absence of clinical signs of light anesthesia until a mild response to surgical stimulation is obtained in order to avoid administration of PROPOFOL at rates higher than are clinically necessary. Generally, rates of 50 mcg/kg/min to 100 mcg/kg/min in adults should be achieved during maintenance in order to optimize recovery times.</p><p>&nbsp;</p><p>Other drugs that cause CNS depression (e.g., sedatives, anesthetics, and opioids) can increase CNS depression induced by Propofol. Morphine premedication (0.15 mg/kg) with nitrous oxide 67% in oxygen has been shown to decrease the necessary Propofol injection maintenance infusion rate and therapeutic blood concentrations when compared to non-narcotic (lorazepam) premedication.</p><p>&nbsp;</p><p>Induction of General Anesthesia Adult Patients</p><p>Most adult patients under 55 years of age and classified as ASA-PS I or II require 2 mg/kg to 2.5 mg/kg of PROPOFOL for induction when unpremedicated or when premedicated with oral benzodiazepines or intramuscular opioids. For induction, PROPOFOL should be titrated (approximately 40 mg every 10 seconds) against the response of the patient until the clinical signs</p><p>&nbsp;</p><p>show the onset of anesthesia. As with other general anesthetics, the amount of intravenous opioid and/or benzodiazepine premedication will influence the response of the patient to an induction dose of PROPOFOL.</p><p>&nbsp;</p><p>Elderly, Debilitated, or ASA-PS III or IV Patients</p><p><strong>&nbsp;</strong></p><p>It is important to be familiar and experienced with the intravenous use of PROPOFOL before treating elderly, debilitated, or ASA-PS III or IV patients. Due to the reduced clearance and higher blood concentrations, most of these patients require approximately 1 mg/kg to 1.5 mg/kg (approximately 20 mg every 10 seconds) of PROPOFOL for induction of anesthesia according to their condition and responses. A rapid bolus should not be used, as this will increase the likelihood of undesirable cardiorespiratory depression including hypotension, apnea, airway obstruction, and/or oxygen desaturation (see <u>DOSAGE AND ADMINISTRATION</u>).</p><p>&nbsp;</p><p>Pediatric Patients</p><p><strong>&nbsp;</strong></p><p>Most patients aged 3 years through 16 years and classified ASA-PS I or II require 2.5 mg/kg to 3.5 mg/kg of PROPOFOL for induction when unpremedicated or when lightly premedicated with oral benzodiazepines or intramuscular opioids. Within this dosage range, younger pediatric patients may require higher induction doses than older pediatric patients. As with other general anesthetics, the amount of intravenous opioid and/or benzodiazepine premedication will influence the response of the patient to an induction dose of PROPOFOL. A lower dosage is recommended for pediatric patients classified as ASA-PS III or IV. Attention should be paid to minimize pain on injection when administering PROPOFOL to pediatric patients. Boluses of PROPOFOL may be administered via small veins if pretreated with lidocaine or via antecubital or larger veins (see <u>PRECAUTIONS</u>, <u>General</u>).</p><p>&nbsp;</p><p>Neurosurgical Patients</p><p><strong>&nbsp;</strong></p><p>Slower induction is recommended using boluses of 20 mg every 10 seconds. Slower boluses or infusions of PROPOFOL for induction of anesthesia, titrated to clinical responses, will generally</p><p>&nbsp;</p><p>result in reduced induction dosage requirements (1 mg/kg to 2 mg/kg) (see <u>PRECAUTIONS</u> and <u>DOSAGE AND ADMINISTRATION</u>).</p><p>&nbsp;</p><p>Cardiac Anesthesia</p><p><strong>&nbsp;</strong></p><p>PROPOFOL has been well-studied in patients with coronary artery disease, but experience in patients with hemodynamically significant valvular or congenital heart disease is limited. As with other general anesthetics and sedation drugs, PROPOFOL in healthy patients causes a decrease in blood pressure that is secondary to decreases in preload (ventricular filling volume at the end of the diastole) and afterload (arterial resistance at the beginning of the systole). The magnitude of these changes is proportional to the blood and effect site concentrations achieved. These concentrations depend upon the dose and speed of the induction and maintenance infusion rates.</p><p>&nbsp;</p><p>In addition, lower heart rates are observed during maintenance with PROPOFOL, possibly due to reduction of the sympathetic activity and/or resetting of the baroreceptor reflexes. Therefore, anticholinergic agents should be administered when increases in vagal tone are anticipated.</p><p>&nbsp;</p><p>As with other anesthetic agents, PROPOFOL reduces myocardial oxygen consumption. Further studies are needed to confirm and delineate the extent of these effects on the myocardium and the coronary vascular system.</p><p>&nbsp;</p><p>Morphine premedication (0.15 mg/kg) with nitrous oxide 67% in oxygen has been shown to decrease the necessary PROPOFOL maintenance infusion rates and therapeutic blood concentrations when compared to non-narcotic (lorazepam) premedication. The rate of PROPOFOL administration should be determined based on the patient&#39;s premedication and adjusted according to clinical responses.</p><p>&nbsp;</p><p>A rapid bolus induction should be avoided. A slow rate of approximately 20 mg every 10 seconds until induction onset (0.5 mg/kg to 1.5 mg/kg) should be used. In order to assure adequate anesthesia, when PROPOFOL is used as the primary agent, maintenance infusion rates should not be less than</p><p>100 mcg/kg/min and should be supplemented with analgesic levels of continuous opioid administration. When an opioid is used as the primary agent, PROPOFOL maintenance rates should not be less than 50 mcg/kg/min, and care should be taken to ensure amnesia. Higher doses of</p><p>&nbsp;</p><p>PROPOFOL will reduce the opioid requirements (see Table 4). When PROPOFOL is used as the primary anesthetic, it should not be administered with the high-dose opioid technique as this may increase the likelihood of hypotension (see <u>PRECAUTIONS, Cardiac Anesthesia</u>).</p><p>&nbsp;</p><p>Table 4. Cardiac Anesthesia Techniques</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Primary agent</p></td><td style="vertical-align:top"><p>Rate</p></td><td style="vertical-align:top"><p>Secondary agent/rate</p><p><strong>&nbsp;</strong></p><p>(Following&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Induction&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with Primary Agent)</p></td></tr><tr><td style="vertical-align:top"><p>PROPOFOL</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>OPIOIDa/0.05 mcg/kg/min to</p><p>0.075&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mcg/kg/min (no bolus)</p></td></tr><tr><td style="vertical-align:top"><p>Preinduction</p><p>Anxiolysis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Induction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance</p><p>(Titrated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Clinical Response)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>OPIOIDb</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>PROPOFOL /50 mcg/kg/min to</p><p>100&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mcg/kg/min</p><p>(no bolus)</p></td></tr><tr><td style="vertical-align:top"><p>Induction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aOPIOID is defined in terms of fentanyl equivalents, i.e., 1 mcg of fentanyl = 5 mcg of alfentanil (for bolus)</p><p>= 10 mcg of alfentanil (for maintenance) or</p><p>= 0.1 mcg of sufentanil</p><p>&nbsp;</p><p>bCare should be taken to ensure amnesia.</p><p>&nbsp;</p><p>Maintenance of General Anesthesia</p><p><strong>&nbsp;</strong></p><p>PROPOFOL has been used with a variety of agents commonly used in anesthesia such as atropine, scopolamine, glycopyrrolate, diazepam, depolarizing and nondepolarizing muscle relaxants, and opioid analgesics, as well as with inhalational and regional anesthetic agents.</p><p>&nbsp;</p><p>In the elderly, debilitated, or ASA-PS III or IV patients, rapid bolus doses should not be used, as this will increase cardiorespiratory effects including hypotension, apnea, airway obstruction, and oxygen desaturation.</p><p>&nbsp;</p><p>Adult Patients</p><p><strong>&nbsp;</strong></p><p>In adults, anesthesia can be maintained by administering PROPOFOL by infusion or intermittent IV bolus injection. The patient&#39;s clinical response will determine the infusion rate or the amount and frequency of incremental injections.</p><p>&nbsp;</p><p>Continuous Infusion</p><p><strong>&nbsp;</strong></p><p>PROPOFOL 100 mcg/kg/min to 200 mcg/kg/min administered in a variable rate infusion with 60% to 70% nitrous oxide and oxygen provides anesthesia for patients undergoing general surgery. Maintenance by infusion of PROPOFOL should immediately follow the induction dose in order to provide satisfactory or continuous anesthesia during the induction phase. During this initial period following the induction dose, higher rates of infusion are generally required (150 mcg/kg/min to 200 mcg/kg/min) for the first 10 minutes to 15 minutes. Infusion rates should subsequently be decreased 30% to 50% during the first half-hour of maintenance. Generally, rates of 50 mcg/kg/min to 100 mcg/kg/min in adults should be achieved during maintenance in order to optimize recovery times.</p><p>&nbsp;</p><p>Other drugs that cause CNS depression (e.g., sedatives, anesthetics, and opioids) can increase the CNS depression induced by Propofol.</p><p>&nbsp;</p><p>Intermittent Bolus</p><p>&nbsp;</p><p>Increments of PROPOFOL 25 mg (2.5 mL) to 50 mg (5 mL) may be administered with nitrous oxide in adult patients undergoing general surgery. The incremental boluses should be administered when changes in vital signs indicate a response to surgical stimulation or light anesthesia.</p><p>&nbsp;</p><p>Pediatric Patients</p><p><strong>&nbsp;</strong></p><p>PROPOFOL administered as a variable rate infusion supplemented with nitrous oxide 60% to 70% provides satisfactory anesthesia for most children 2 months of age or older, ASA-PS I or II, undergoing general anesthesia.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; In general, for the pediatric population, maintenance by infusion of PROPOFOL at a rate of</p><p>200 mcg/kg/min to 300 mcg/kg/min should immediately follow the induction&nbsp; dose. Following the first half-hour of maintenance, infusion rates of 125 mcg/kg/min to 150 mcg/kg/min are typically needed. PROPOFOL should be titrated to achieve the desired clinical effect. Younger pediatric patients may require higher maintenance infusion rates than older pediatric patients. (See Table 2 Clinical Trials.)</p><p>&nbsp;</p><p>Monitored Anesthesia Care (MAC) Sedation Adult Patients</p><p>When PROPOFOL is administered for MAC sedation, rates of administration should be individualized and titrated to clinical response. In most patients, the rates of PROPOFOL administration will be in the range of 25 mcg/kg/min to 75 mcg/kg/min.</p><p>&nbsp;</p><p>During initiation of MAC sedation, slow infusion or slow injection techniques are preferable over rapid bolus administration. During maintenance of MAC sedation, a variable rate infusion is preferable over intermittent bolus dose administration. In the elderly, debilitated, or ASA-PS III or IV patients, rapid (single or repeated) bolus dose administration should not be used for MAC sedation (see <u>WARNINGS</u>). A rapid bolus injection can result in undesirable cardiorespiratory depression including hypotension, apnea, airway obstruction, and oxygen desaturation.</p><p>&nbsp;</p><p>Initiation of MAC Sedation</p><p><strong>&nbsp;</strong></p><p>For initiation of MAC sedation, either an infusion or a slow injection method may be utilized while closely monitoring cardiorespiratory function. With the infusion method, sedation may be initiated by infusing PROPOFOL at 100 mcg/kg/min to 150 mcg/kg/min (6 mg/kg/h to 9 mg/kg/h) for a period of 3 minutes to 5 minutes and titrating to the desired clinical effect while closely monitoring respiratory function. With the slow injection method for initiation, patients will require approximately 0.5 mg/kg administered over 3 minutes to 5 minutes and titrated to clinical responses. When PROPOFOL is administered slowly over 3 minutes to 5 minutes, most patients will be adequately sedated, and the peak drug effect can be achieved while minimizing undesirable cardiorespiratory effects occurring at high plasma levels.</p><p>&nbsp;</p><p>In the elderly, debilitated, or ASA-PS III or IV patients, rapid (single or repeated) bolus dose administration should not be used for MAC sedation (see <u>WARNINGS</u>). The rate of administration should be over 3 minutes to 5 minutes and the dosage of PROPOFOL should be reduced to approximately 80% of the usual adult dosage in these patients according to their condition, responses, and changes in vital signs (see <u>DOSAGE AND ADMINISTRATION</u>).</p><p>&nbsp;</p><p>Maintenance of MAC Sedation</p><p><strong>&nbsp;</strong></p><p>For maintenance of sedation, a variable rate infusion method is preferable over an intermittent bolus dose method. With the variable rate infusion method, patients will generally require maintenance rates of 25 mcg/kg/min to 75 mcg/kg/min (1.5 mg/kg/h to 4.5 mg/kg/h) during the first 10 minutes to 15 minutes of sedation maintenance. Infusion rates should subsequently be decreased over time to 25 mcg/kg/min to 50 mcg/kg/min and adjusted to clinical responses. In titrating to clinical effect, allow approximately 2 minutes for onset of peak drug effect.</p><p>&nbsp;</p><p>Infusion rates should always be titrated downward in the absence of clinical signs of light sedation until mild responses to stimulation are obtained in order to avoid sedative administration of PROPOFOL at rates higher than are clinically necessary.</p><p>&nbsp;</p><p>If the intermittent bolus dose method is used, increments of PROPOFOL 10 mg (1 mL) or 20 mg (2 mL) can be administered and titrated to desired clinical effect. With the intermittent bolus method of sedation maintenance, there is increased potential for respiratory depression, transient increases in sedation depth, and prolongation of recovery.</p><p>&nbsp;</p><p>In the elderly, debilitated, or ASA-PS III or IV patients, rapid (single or repeated) bolus dose administration should not be used for MAC sedation (see <u>WARNINGS</u>). The rate of administration and the dosage of PROPOFOL should be reduced to approximately 80% of the usual adult dosage in these patients according to their condition, responses, and changes in vital signs (see <u>DOSAGE AND</u> <u>ADMINISTRATION</u>).</p><p>&nbsp;</p><p>PROPOFOL can be administered as the sole agent for maintenance of MAC sedation during surgical/diagnostic procedures. When PROPOFOL sedation is supplemented with opioid and/or benzodiazepine medications, these agents increase the sedative and respiratory effects of PROPOFOL and may also result in a slower recovery profile (see <u>PRECAUTIONS</u>, <u>Drug</u> <u>Interactions</u>).</p><p>&nbsp;</p><p>ICU Sedation</p><p><strong>&nbsp;</strong></p><p>(See <u>WARNINGS</u> and <u>DOSAGE AND ADMINISTRATION</u>, <u>Handling Procedures</u>.)</p><p>&nbsp;</p><p>Abrupt discontinuation of PROPOFOL prior to weaning or for daily evaluation of sedation levels should be avoided. This may result in rapid awakening with associated anxiety, agitation, and resistance to mechanical ventilation. Infusions of PROPOFOL should be adjusted to assure a minimal level of sedation is maintained throughout the weaning process and when assessing the level of sedation (see <u>PRECAUTIONS</u>).</p><p>&nbsp;</p><p>Adult Patients</p><p>&nbsp;</p><p>For intubated, mechanically ventilated adult patients, Intensive Care Unit (ICU) sedation should be initiated slowly with a continuous infusion in order to titrate to desired clinical effect and minimize hypotension (see <u>DOSAGE AND ADMINISTRATION</u>).</p><p>&nbsp;</p><p>Most adult ICU patients recovering from the effects of general anesthesia or deep sedation will require maintenance rates of 5 mcg/kg/min to 50 mcg/kg/min (0.3 mg/kg/h to 3 mg/kg/h) individualized and titrated to clinical response (see <u>DOSAGE AND ADMINISTRATION</u>). With medical ICU patients or patients who have recovered from the effects of general anesthesia or deep sedation, the rate of administration of 50 mcg/kg/min or higher may be required to achieve adequate sedation. These higher rates of administration may increase the likelihood of patients developing hypotension. Administration should not exceed 4 mg/kg/hour unless the benefits outweigh the risks (see <u>WARNINGS</u>).</p><p>&nbsp;</p><p>Dosage and rate of administration should be individualized and titrated to the desired effect, according to clinically relevant factors including the patient&rsquo;s underlying medical problems, preinduction and concomitant medications, age, ASA-PS classification, and level of debilitation of the patient. The elderly, debilitated, and ASA-PS III or IV patients may have exaggerated hemodynamic and respiratory responses to rapid bolus doses (see <u>WARNINGS</u>).</p><p>&nbsp;</p><p>PROPOFOL should be individualized according to the patient&#39;s condition and response, blood lipid profile, and vital signs (see <u>PRECAUTIONS</u>, <u>Intensive Care Unit Sedation</u>). For intubated, mechanically ventilated adult patients, Intensive Care Unit (ICU) sedation should be initiated slowly with a continuous infusion in order to titrate to desired clinical effect and minimize hypotension. When indicated, initiation of sedation should begin at 5 mcg/kg/min (0.3 mg/kg/h). The infusion rate should be increased by increments of 5 mcg/kg/min to 10 mcg/kg/min (0.3 mg/kg/h to 0.6 mg/kg/h) until the desired level of sedation is achieved. A minimum period of 5 minutes between adjustments should be allowed for onset of peak drug effect. Most adult patients require maintenance rates of 5 mcg/kg/min to 50 mcg/kg/min (0.3 mg/kg/h to 3 mg/kg/h) or higher. Administration should not exceed 4 mg/kg/hour unless the benefits outweigh the risks (see <u>WARNINGS</u>). Dosages of PROPOFOL should be reduced in patients who have received large dosages of narcotics. The PROPOFOL dosage requirement may also be reduced by adequate management of pain with analgesic agents. As with other sedative medications, there is interpatient variability in dosage requirements, and these requirements may change with time (see <u>SUMMARY OF DOSAGE</u> <u>GUIDELINES</u>). Evaluation of level of sedation and assessment of CNS function should be carried out daily throughout maintenance to determine the minimum dose of PROPOFOL required for</p><p>&nbsp;</p><p>sedation (see <u>Clinical Trials</u>, <u>Intensive Care Unit (ICU) Sedation</u>). Bolus administration of 10 mg or 20 mg should only be used to rapidly increase depth of sedation in patients where hypotension is not likely to occur. Patients with compromised myocardial function, intravascular volume depletion, or abnormally low vascular tone (e.g., sepsis) may be more susceptible to hypotension (see <u>PRECAUTIONS</u>).</p><p>&nbsp;</p><p>SUMMARY OF DOSAGE GUIDELINES:</p><p><strong>&nbsp;</strong></p><p>Dosages and rates of administration in the following table should be individualized and titrated to clinical response. Safety and dosing requirements for induction of anesthesia in pediatric patients have only been established for children 3 years of age or older. Safety and dosing requirements for the maintenance of anesthesia have only been established for children 2 months of age and older.</p><p>&nbsp;</p><p>For complete dosage information, see <u>DOSAGE AND ADMINISTRATION</u></p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>INDICATION</strong></p></td><td style="vertical-align:top"><p><strong>DOSAGE AND ADMINISTRATION</strong></p></td></tr><tr><td style="vertical-align:top"><p>Induction of General Anesthesia:</p></td><td style="vertical-align:top"><p>Healthy Adults Less&nbsp; Than&nbsp; 55&nbsp; Years&nbsp; of&nbsp; Age: 40 mg every 10 seconds until induction onset (2 mg/kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg/kg). Elderly, Debilitated, or ASA-PS III or IV Patients:</p><p>20 mg every 10 seconds until induction onset (1 mg/kg&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg/kg).</p><p>Cardiac&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anesthesia:</p><p>20 mg every 10 seconds until induction&nbsp; onset (0.5 mg/kg&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg/kg). Neurosurgical&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients:</p><p>20 mg every 10 seconds until induction onset (1 mg/kg&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg/kg). Pediatric Patients - healthy, from 3 years to 16</p><p>years&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; age:</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>2.5 mg/kg to 3.5 mg/kg administered over 20 seconds to 30 seconds. (see <u>PRECAUTIONS</u>,<u> Pediatric&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use</u> and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>CLINICAL</u></p><p><u>PHARMACOLOGY, Pediatrics</u>).</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of General Anesthesia:</p></td><td style="vertical-align:top"><p>Infusion</p><p>Healthy Adults Less Than 55&nbsp; Years&nbsp; of&nbsp; Age: 100 mcg/kg/min to 200 mcg/kg/min (6 mg/kg/h to12mg/kg/h).</p><p>Elderly, Debilitated, ASA-PS III or IV Patients: 50 mcg/kg/min to 100 mcg/kg/min (3 mg/kg/h to 6mg/kg/h).</p><p>Cardiac Anesthesia: Most patients require: Primary PROPOFOL with Secondary Opioid &ndash; 100mcg/kg/minto150mcg/kg/min.</p><p>Low-Dose PROPOFOL with Primary Opioid &ndash;</p><p>50&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mcg/kg/minto100mcg/kg/min. (see DOSAGE AND ADMINISTRATION, Table4).</p><p>Neurosurgical&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients:</p><p>100 mcg/kg/min to 200 mcg/kg/min (6 mg/kg/h to12mg/kg/h).</p><p>Pediatric Patients - healthy, from 2 months of age to16yearsofage:</p><p>125 mcg/kg/min to 300 mcg/kg/min (7.5 mg/kg/h to 18 mg/kg/h). Following the first half hour of maintenance, if clinical signs of light anesthesia are not present, the infusion rate should be decreased.</p><p>(see <u>PRECAUTIONS</u>, <u>Pediatric Use</u> and</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><u>CLINICAL PHARMACOLOGY, Pediatrics</u>).</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of General Anesthesia:</p></td><td style="vertical-align:top"><p>Intermittent&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bolus</p><p>Healthy Adults Less Than 55 Years of Age: Increments of 20 mg to 50 mg as needed.</p></td></tr><tr><td style="vertical-align:top"><p>Initiation of MAC Sedation:</p></td><td style="vertical-align:top"><p>Healthy Adults Less Than 55 Years of&nbsp; Age: Slow infusion or slow injection techniques are recommended to avoid apnea or hypotension. Most patients require an infusion of 100 mcg/kg/min to 150 mcg/kg/min (6 mg/kg/h to 9 mg/kg/h) for 3 minutes to 5 minutes or a slow injection of 0.5 mg/kg over 3 minutes to 5 minutes followed immediately by a maintenance infusion.</p><p>Elderly, Debilitated, Neurosurgical, or ASA-PS III&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IV&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients: Most patients require dosages similar to healthy adults.</p><p>Rapid boluses are to be avoided (see</p><p><u>WARNINGS</u>).</p></td></tr><tr><td style="vertical-align:top"><p>Maintenance of MAC Sedation:</p></td><td style="vertical-align:top"><p>Healthy Adults&nbsp; Less&nbsp; Than&nbsp; 55&nbsp; Years&nbsp; of&nbsp; Age: A variable rate infusion technique is preferable over an intermittent bolus technique. Most patients require an infusion of 25 mcg/kg/min to 75 mcg/kg/min (1.5 mg/kg/h to 4.5 mg/kg/h) or incremental bolus doses of 10&nbsp; mg&nbsp; or&nbsp; 20&nbsp; mg.&nbsp; In Elderly, Debilitated, Neurosurgical, or ASA- PS&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; III&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; IV&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Patients: Most &nbsp;patients &nbsp;require &nbsp;80% &nbsp;of &nbsp;the &nbsp;usual &nbsp;adult</p><p>dose.&nbsp; A&nbsp; rapid&nbsp; (single&nbsp; or&nbsp; repeated)&nbsp; bolus &nbsp;dose</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>should not be used (see <u>WARNINGS</u>).</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Initiation and Maintenance of ICU Sedation in Intubated, Mechanically Ventilated</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Adult Patients - Because of the residual effects of previous anesthetic or sedative agents, in most patients the initial infusion should be 5 mcg/kg/min (0.3 mg/kg/h) for at least 5 minutes. Subsequent increments of 5 mcg/kg/min to 10 mcg/kg/min (0.3 mg/kg/h to 0.6 mg/kg/h) over 5 minutes to 10 minutes may be used until desired clinical effect is achieved. Maintenance rates of 5 mcg/kg/min to 50 mcg/kg/min (0.3 mg/kg/h to 3 mg/kg/h) or higher may be required. Administration should not exceed 4 mg/kg/hour unless the benefits outweigh the risks (see <u>WARNINGS</u>).</p><p>Evaluation of clinical effect and assessment of CNS function should be carried out daily throughout maintenance to determine the minimum dose of PROPOFOL required for sedation.</p><p>The tubing and any unused PROPOFOL drug product should be discarded after 12 hours because PROPOFOL contains no preservatives and is capable of supporting growth of microorganisms</p><p>(see <u>WARNINGS</u>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>DOSAGE&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; AND</u></p><p><u>ADMINISTRATION</u>).</p></td></tr></tbody></table><p>&nbsp;</p><p>Administration with Lidocaine</p><p>&nbsp;</p><p>If lidocaine is to be administered to minimize pain on injection of PROPOFOL, it is recommended that it be administered prior to PROPOFOL administration or that it be added to PROPOFOL immediately before administration and in quantities not exceeding 20 mg lidocaine/200 mg PROPOFOL.</p><p>&nbsp;</p><p>Compatibility and Stability</p><p><strong>&nbsp;</strong></p><p>PROPOFOL should not be mixed with other therapeutic agents prior to administration.</p><p>&nbsp;</p><p>Dilution Prior to Administration</p><p><strong>&nbsp;</strong></p><p>PROPOFOL is provided as a ready-to-use formulation. However, should dilution be necessary, it should only be diluted with 5% Dextrose Injection, USP, and it should not be diluted to a concentration less than 2 mg/mL because it is an emulsion. In diluted form it has been shown to be more stable when in contact with glass than with plastic (95% potency after 2 hours of running infusion in plastic).</p><p>&nbsp;</p><p>Administration with Other Fluids</p><p><strong>&nbsp;</strong></p><p>Compatibility of PROPOFOL with the coadministration of blood/serum/plasma has not been established (see <u>WARNINGS</u>). When administered using a y-type infusion set, PROPOFOL has been shown to be compatible with the following intravenous fluids.</p><p>&nbsp;</p><p>-&nbsp; 5% Dextrose Injection, USP</p><p>&nbsp;</p><p>-&nbsp; Lactated Ringers Injection, USP</p><p>&nbsp;</p><p>-&nbsp; Lactated Ringers and 5% Dextrose Injection</p><p>&nbsp;</p><p>-&nbsp; 5% Dextrose and 0.45% Sodium Chloride Injection, USP</p><p>&nbsp;</p><p>-&nbsp; 5% Dextrose and 0.2% Sodium Chloride Injection, USP</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                PROPOFOL is contraindicated in patients with a known hypersensitivity to Propofol or any of PROPOFOL components.

PROPOFOL is contraindicated in patients with allergies to eggs, egg products, soybeans or soy products.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Warnings</p><p><strong>&nbsp;</strong></p><p>Use of PROPOFOL has been associated with both fatal and life-threatening anaphylactic and anaphylactoid reactions.</p><p>&nbsp;</p><p>For general anesthesia or monitored anesthesia care (MAC) sedation, PROPOFOL should be administered only by persons trained in the administration of general anesthesia and not involved in the conduct of the surgical/diagnostic procedure. Sedated patients should be continuously monitored, and facilities for maintenance of a patent airway, providing artificial ventilation, administering supplemental oxygen, and instituting cardiovascular resuscitation must be immediately available. Patients should be continuously monitored for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation. These cardiorespiratory effects are more likely to occur following rapid bolus administration, especially in the elderly, debilitated, or ASA-PS III or IV patients.</p><p>&nbsp;</p><p>For sedation of intubated, mechanically ventilated patients in the Intensive Care Unit (ICU), PROPOFOL should be administered only by persons skilled in the management of critically ill patients and trained in cardiovascular resuscitation and airway management.</p><p>&nbsp;</p><p>Use of PROPOFOL infusions for both adult and pediatric ICU sedation has been associated with a constellation of metabolic derangements and organ system failures, referred to as Propofol Infusion Syndrome, that have resulted in death. The syndrome is characterized by severe metabolic acidosis, hyperkalemia, lipemia, rhabdomyolysis, hepatomegaly, renal failure, ECG changes* and/or cardiac failure. The following appear to be major risk factors for the development of these events: decreased</p><p>&nbsp;</p><p>oxygen delivery to tissues; serious neurological injury and/or sepsis; high dosages of one or more of the following pharmacological agents: vasoconstrictors, steroids, inotropes and/or prolonged, high- dose infusions of Propofol (greater than 5 mg/kg/h for greater than 48h). The syndrome has also been reported following large-dose, short-term infusions during surgical anesthesia. In the setting of prolonged need for sedation, increasing Propofol dose requirements to maintain a constant level of sedation, or onset of metabolic acidosis during administration of a Propofol infusion, consideration should be given to using alternative means of sedation.</p><p>&nbsp;</p><p>*Coved ST segment elevation (similar to ECG changes of the Brugada syndrome).</p><p>&nbsp;</p><p>Abrupt discontinuation of PROPOFOL prior to weaning or for daily evaluation of sedation levels should be avoided. This may result in rapid awakening with associated anxiety, agitation, and resistance to mechanical ventilation. Infusions of PROPOFOL should be adjusted to maintain a light level of sedation through the weaning process or evaluation of sedation level (see <u>PRECAUTIONS</u>).</p><p>&nbsp;</p><p>PROPOFOL should not be coadministered through the same IV catheter with blood or plasma because compatibility has not been established. In vitro tests have shown that aggregates of the globular component of the emulsion vehicle have occurred with blood/plasma/serum from humans and animals. The clinical significance of these findings is not known.</p><p>&nbsp;</p><p>There have been reports in which failure to use aseptic technique when handling PROPOFOL was associated with microbial contamination of the product and with fever, infection, sepsis, other life- threatening illness, and death. Do not use if contamination is suspected. Discard unused drug product as directed within the required time limits (see <u>DOSAGE AND ADMINISTRATION</u>, <u>Handling</u> <u>Procedures</u>).</p><p>&nbsp;</p><p>There have been reports, in the literature and other public sources, of the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C, and HIV) from unsafe injection practices, and use of Propofol vials intended for single use on multiple persons. PROPOFOL vial is never to be accessed more than once or used on more than one person.</p><p>&nbsp;</p><p>Pediatric Neurotoxicity</p><p>&nbsp;</p><p>Published animal studies demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity increase neuronal apoptosis in the developing brain and result in long-term cognitive deficits when used for longer than 3 hours. The clinical significance of these findings is not clear. However, based on the available data, the window of vulnerability to these changes is believed to correlate with exposures in the third trimester of gestation through the first several months of life, but may extend out to approximately three years of age in humans (see <u>PRECAUTIONS</u>, <u>Pregnancy</u>, <u>Pediatric Use</u>; <u>ANIMAL TOXICOLOGY</u> <u>AND/OR PHARMACOLOGY</u>).</p><p>&nbsp;</p><p>Some published studies in children suggest that similar deficits may occur after repeated or prolonged exposures to anesthetic agents early in life and may result in adverse cognitive or behavioral effects. These studies have substantial limitations, and it is not clear if the observed effects are due to the anesthetic/sedation drug administration or other factors such as the surgery or underlying illness.</p><p>&nbsp;</p><p>Anesthetic and sedation drugs are a necessary part of the care of children needing surgery, other procedures, or tests that cannot be delayed, and no specific medications have been shown to be safer than any other. Decisions regarding the timing of any elective procedures requiring anesthesia should take into consideration the benefits of the procedure weighed against the potential risks.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Precautions:</p><p><strong>&nbsp;</strong></p><p><strong>General</strong></p><p><strong>&nbsp;</strong></p><p>Adult and Pediatric Patients</p><p>&nbsp;</p><p>A lower induction dose and a slower maintenance rate of administration should be used in elderly, debilitated, or ASA-PS III or IV patients (see <u>DOSAGE AND ADMINISTRATION</u>). Patients should be continuously monitored for early signs of hypotension and/or bradycardia. Apnea requiring ventilatory support often occurs during induction and may persist for more than 60 seconds.</p><p>&nbsp;</p><p>PROPOFOL use requires caution when administered to patients with disorders of lipid metabolism such as primary hyperlipoproteinemia, diabetic hyperlipemia, and pancreatitis.</p><p>&nbsp;</p><p>Very rarely the use of PROPOFOL may be associated with the development of a period of postoperative unconsciousness which may be accompanied by an increase in muscle tone. This may or may not be preceded by a brief period of wakefulness. Recovery is spontaneous.</p><p>&nbsp;</p><p>When PROPOFOL is administered to an epileptic patient, there is a risk of seizure during the recovery phase.</p><p>&nbsp;</p><p>Attention should be paid to minimize pain on administration of PROPOFOL. Transient local pain can be minimized if the larger veins of the forearm or antecubital fossa are used. Pain during intravenous injection may also be reduced by prior injection of IV lidocaine (1 mL of a 1% solution). Pain on injection occurred frequently in pediatric patients (45%) when a small vein of the hand was utilized without lidocaine pretreatment. With lidocaine pretreatment or when antecubital veins were utilized, pain was minimal (incidence less than 10%) and well-tolerated. There have been reports in the literature indicating that the addition of lidocaine to PROPOFOL in quantities greater than 20 mg lidocaine/200 mg PROPOFOL results in instability of the emulsion which is associated with increases in globule sizes over time and (in rat studies) a reduction in anesthetic potency. Therefore, it is recommended that lidocaine be administered prior to PROPOFOL administration or that it be added to PROPOFOL immediately before administration and in quantities not exceeding 20 mg lidocaine/200 mg PROPOFOL.</p><p>&nbsp;</p><p>Venous sequelae, i.e., phlebitis or thrombosis, have been reported rarely (less than 1%). In two clinical studies using dedicated intravenous catheters, no instances of venous sequelae were observed up to 14 days following induction.</p><p>&nbsp;</p><p>Intra-arterial injection in animals did not induce local tissue effects. Accidental intra-arterial injection has been reported in patients, and, other than pain, there were no major sequelae.</p><p>&nbsp;</p><p>Intentional injection into subcutaneous or perivascular tissues of animals caused minimal tissue reaction. During the post-marketing period, there have been rare reports of local pain, swelling, blisters, and/or tissue necrosis following accidental extravasation of PROPOFOL.</p><p>&nbsp;</p><p>Perioperative myoclonia, rarely including convulsions and opisthotonos, has occurred in association with PROPOFOL administration.</p><p>&nbsp;</p><p>Clinical features of anaphylaxis, including angioedema, bronchospasm, erythema, and hypotension, occur rarely following PROPOFOL administration.</p><p>&nbsp;</p><p>There have been rare reports of pulmonary edema in temporal relationship to the administration of PROPOFOL, although a causal relationship is unknown.</p><p>&nbsp;</p><p>Rarely, cases of unexplained postoperative pancreatitis (requiring hospital admission) have been reported after anesthesia in which PROPOFOL was one of the induction agents used. Due to a variety of confounding factors in these cases, including concomitant medications, a causal relationship to PROPOFOL is unclear.</p><p>&nbsp;</p><p>PROPOFOL has no vagolytic activity. Reports of bradycardia, asystole, and rarely, cardiac arrest have been associated with PROPOFOL. Pediatric patients are susceptible to this effect, particularly when fentanyl is given concomitantly. The intravenous administration of anticholinergic agents (e.g., atropine or glycopyrrolate) should be considered to modify potential increases in vagal tone due to concomitant agents (e.g., succinylcholine) or surgical stimuli.</p><p>&nbsp;</p><p>Intensive Care Unit Sedation</p><p><strong>&nbsp;</strong></p><p>Adult Patients</p><p>&nbsp;</p><p>(See <u>WARNINGS</u> and <u>DOSAGE AND ADMINISTRATION</u>, <u>Handling Procedures</u>.) The administration of PROPOFOL should be initiated as a continuous infusion and changes in the rate of administration made slowly (greater than 5 min) in order to minimize hypotension and avoid acute overdosage (see <u>DOSAGE AND ADMINISTRATION</u>).</p><p>&nbsp;</p><p>Patients should be monitored for early signs of significant hypotension and/or cardiovascular depression, which may be profound. These effects are responsive to discontinuation of PROPOFOL, IV fluid administration, and/or vasopressor therapy. In the elderly, debilitated, or ASA-PS III or IV patients, rapid (single or repeated) bolus administration should not be used during sedation in order to minimize undesirable cardiorespiratory depression, including hypotension, apnea, airway obstruction, and oxygen desaturation.</p><p>&nbsp;</p><p>As with other sedative medications, there is wide interpatient variability in PROPOFOL dosage requirements, and these requirements may change with time.</p><p>&nbsp;</p><p>Failure to reduce the infusion rate in patients receiving PROPOFOL for extended periods may result in excessively high blood concentrations of the drug. Thus, titration to clinical response and daily evaluation of sedation levels are important during use of PROPOFOL infusion for ICU sedation, especially when it is used for long durations.</p><p>&nbsp;</p><p>Opioids and paralytic agents should be discontinued and respiratory function optimized prior to weaning patients from mechanical ventilation. Infusions of PROPOFOL should be adjusted to maintain a light level of sedation prior to weaning patients from mechanical ventilatory support. Throughout the weaning process, this level of sedation may be maintained in the absence of respiratory depression. Because of the rapid clearance of PROPOFOL, abrupt discontinuation of a patient&#39;s infusion may result in rapid awakening with associated anxiety, agitation, and resistance to mechanical ventilation, making weaning from mechanical ventilation difficult. It is therefore recommended that administration of PROPOFOL be continued in order to maintain a light level of sedation throughout the weaning process until 10 minutes to 15 minutes prior to extubation, at which time the infusion can be discontinued.</p><p>&nbsp;</p><p>Since PROPOFOL is formulated in an oil-in-water emulsion, elevations in serum triglycerides may occur when PROPOFOL is administered for extended periods of time. Patients at risk of hyperlipidemia should be monitored for increases in serum triglycerides or serum turbidity. Administration of PROPOFOL should be adjusted if fat is being inadequately cleared from the body. A reduction in the quantity of concurrently administered lipids is indicated to compensate for the</p><p>&nbsp;</p><p>amount of lipid infused as part of the PROPOFOL formulation; 1 mL of PROPOFOL contains approximately 0.1 g of fat (1.1 kcal).</p><p>&nbsp;</p><p>EDTA is a strong chelator of trace metals &ndash; including zinc. Although with PROPOFOL there are no reports of decreased zinc levels or zinc deficiency-related adverse events, PROPOFOL should not be infused for longer than 5 days without providing a drug holiday to safely replace estimated or measured urine zinc losses.</p><p>&nbsp;</p><p>In clinical trials mean urinary zinc loss was approximately 2.5 mg/day to 3 mg/day in adult patients and 1.5 mg/day to 2 mg/day in pediatric patients.</p><p>&nbsp;</p><p>In patients who are predisposed to zinc deficiency, such as those with burns, diarrhea, and/or major sepsis, the need for supplemental zinc should be considered during prolonged therapy with PROPOFOL.</p><p>&nbsp;</p><p>At high doses (2 grams to 3 grams per day), EDTA has been reported, on rare occasions, to be toxic to the renal tubules. Studies to date in patients with normal or impaired renal function have not shown any alteration in renal function with PROPOFOL containing 0.005% disodium edetate. In patients at risk for renal impairment, urinalysis and urine sediment should be checked before initiation of sedation and then be monitored on alternate days during sedation.</p><p>&nbsp;</p><p>The long-term administration of PROPOFOL to patients with renal failure and/or hepatic insufficiency has not been evaluated.</p><p>&nbsp;</p><p>Neurosurgical Anesthesia</p><p><strong>&nbsp;</strong></p><p>When PROPOFOL is used in patients with increased intracranial pressure or impaired cerebral circulation, significant decreases in mean arterial pressure should be avoided because of the resultant decreases in cerebral perfusion pressure. To avoid significant hypotension and decreases in cerebral perfusion pressure, an infusion or slow bolus of approximately 20 mg every 10 seconds should be utilized instead of rapid, more frequent, and/or larger boluses of PROPOFOL. Slower induction, titrated to clinical responses, will generally result in reduced induction dosage requirements (1 mg/kg</p><p>&nbsp;</p><p>to 2 mg/kg). When increased ICP is suspected, hyperventilation and hypocarbia should accompany the administration of PROPOFOL (see <u>DOSAGE AND ADMINISTRATION</u>).</p><p>&nbsp;</p><p>Cardiac Anesthesia</p><p><strong>&nbsp;</strong></p><p>Slower rates of administration should be utilized in premedicated patients, geriatric patients, patients with recent fluid shifts, and patients who are hemodynamically unstable. Fluid deficits should be corrected prior to administration of PROPOFOL. In those patients where additional fluid therapy may be contraindicated, other measures, e.g., elevation of lower extremities, or use of pressor agents, may be useful to offset the hypotension which is associated with the induction of anesthesia with PROPOFOL.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The induction dose requirements of PROPOFOL may be reduced in patients with intramuscular or intravenous premedication, particularly with narcotics (e.g., morphine, meperidine, and fentanyl, etc.) and combinations of opioids and sedatives (e.g., benzodiazepines, barbiturates, chloral hydrate, droperidol, etc.). These agents may increase the anesthetic or sedative effects of PROPOFOL and may also result in more pronounced decreases in systolic, diastolic, and mean arterial pressures and cardiac output.</p><p>&nbsp;</p><p>During maintenance of anesthesia or sedation, the rate of PROPOFOL administration should be adjusted according to the desired level of anesthesia or sedation and may be reduced in the presence of supplemental analgesic agents (e.g., nitrous oxide or opioids). The concurrent administration of potent inhalational agents (e.g., isoflurane, enflurane, and halothane) during maintenance with PROPOFOL has not been extensively evaluated. These inhalational agents can also be expected to increase the anesthetic or sedative and cardiorespiratory effects of PROPOFOL.</p><p>&nbsp;</p><p>The concomitant use of valproate and Propofol may lead to increased blood levels of Propofol. Reduce the dose of Propofol when co-administering with valproate. Monitor patients closely for signs of increased sedation or cardiorespiratory depression.</p><p>&nbsp;</p><p>PROPOFOL does not cause a clinically significant change in onset, intensity or duration of action of the commonly used neuromuscular blocking agents (e.g., succinylcholine and nondepolarizing muscle relaxants).</p><p>&nbsp;</p><p>No significant adverse interactions with commonly used premedications or drugs used during anesthesia or sedation (including a range of muscle relaxants, inhalational agents, analgesic agents, and local anesthetic agents) have been observed in adults. In pediatric patients, administration of fentanyl concomitantly with PROPOFOL may result in serious bradycardia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; Impairment of Fertility</p><p>Female Wistar rats administered either 0, 10, or 15 mg/kg/day Propofol intravenously from 2 weeks before pregnancy to day 7 of gestation did not show impaired fertility (0.65 and 1 times the human induction dose of 2.5 mg/kg based on body surface area). Male fertility in rats was not affected in a dominant lethal study at intravenous doses up to 15 mg/kg/day for 5 days.</p><p>&nbsp;</p><p>Pregnancy</p><p><strong>&nbsp;</strong></p><p>RiskSummary</p><p>There are no adequate and well-controlled studies in pregnant women. In animal reproduction studies, decreased pup survival concurrent with increased maternal mortality was observed with intravenous administration of Propofol to pregnant rats either prior to mating and during early gestation or during late gestation and early lactation at exposures less than the human induction dose of 2.5 mg/kg. In pregnant rats administered 15 mg/kg/day intravenous Propofol (equivalent to the human induction dose) from two weeks prior to mating to early in gestation (Gestation Day 7), offspring that were allowed to mate had increased postimplantation losses. The pharmacological activity (anesthesia) of the drug on the mother is probably responsible for the adverse effects seen in the offspring.</p><p>&nbsp;</p><p>Published studies in pregnant primates demonstrate that the administration of anesthetic and sedation drugs that block NMDA receptors and/or potentiate GABA activity during the period of peak brain development increases neuronal apoptosis in the developing brain of the offspring when used for longer than 3 hours. There are no data on pregnancy exposures in primates corresponding to periods prior to the third trimester in humans [See Data].</p><p>&nbsp;</p><p>The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p><p>&nbsp;</p><p>Labor and Delivery</p><p><strong>&nbsp;</strong></p><p>PROPOFOL is not recommended for obstetrics, including cesarean section deliveries. PROPOFOL crosses the placenta, and as with other general anesthetic agents, the administration of PROPOFOL may be associated with neonatal depression.</p><p>&nbsp;</p><p>Nursing Mothers</p><p><strong>&nbsp;</strong></p><p>PROPOFOL is not recommended for use in nursing mothers because PROPOFOL has been reported to be excreted in human milk and the effects of oral absorption of small amounts of Propofol are not known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients should be advised that performance of activities requiring mental alertness, such as operating a motor vehicle, or hazardous machinery or signing legal documents may be impaired for some time after general anesthesia or sedation.</p><p>&nbsp;</p><p>Effect of Anesthetic and Sedation Drugs on Early Brain Development</p><p>&nbsp;</p><p>Studies conducted in young animals and children suggest repeated or prolonged use of general anesthetic or sedation drugs in children younger than 3 years may have negative effects on their</p><p>&nbsp;</p><p>developing brains. Discuss with parents and caregivers the benefits, risks, and timing and duration of surgery or procedures requiring anesthetic and sedation drugs (see <u>WARNINGS, Pediatric</u> <u>Neurotoxicity</u>).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; General</p><p>Adverse event information is derived from controlled clinical trials and worldwide marketing experience. In the description below, rates of the more common events represent US/Canadian clinical study results. Less frequent events are also derived from publications and marketing experience in over 8 million patients; there are insufficient data to support an accurate estimate of their incidence rates. These studies were conducted using a variety of premedicants, varying lengths of surgical/diagnostic procedures, and various other anesthetic/sedative agents. Most adverse events were mild and transient.</p><p>&nbsp;</p><p>Anesthesia and MAC Sedation in Adults</p><p><strong>&nbsp;</strong></p><p>The following estimates of adverse events for PROPOFOL include data from clinical trials in general anesthesia/MAC sedation (N=2,889 adult patients). The adverse events listed below as probably causally related are those events in which the actual incidence rate in patients treated with PROPOFOL was greater than the comparator incidence rate in these trials. Therefore, incidence rates for anesthesia and MAC sedation in adults generally represent estimates of the percentage of clinical trial patients which appeared to have probable causal relationship.</p><p>&nbsp;</p><p>The adverse experience profile from reports of 150 patients in the MAC sedation clinical trials is similar to the profile established with PROPOFOL during anesthesia (see below). During MAC sedation clinical trials, significant respiratory events included cough, upper airway obstruction, apnea, hypoventilation, and dyspnea.</p><p>&nbsp;</p><p>Anesthesia in Pediatric Patients</p><p>&nbsp;</p><p>Generally the adverse experience profile from reports of 506 PROPOFOL pediatric patients from 6 days through 16 years of age in the US/Canadian anesthesia clinical trials is similar to the profile established with PROPOFOL during anesthesia in adults (see Pediatric percentages [Peds %] below). Although not reported as an adverse event in clinical trials, apnea is frequently observed in pediatric patients.</p><p>&nbsp;</p><p>ICU Sedation in Adults</p><p><strong>&nbsp;</strong></p><p>The following estimates of adverse events include data from clinical trials in ICU sedation (N=159 adult patients). Probably related incidence rates for ICU sedation were determined by individual case report form review. Probable causality was based upon an apparent dose response relationship and/or positive responses to rechallenge. In many instances the presence of concomitant disease and concomitant therapy made the causal relationship unknown. Therefore, incidence rates for ICU sedation generally represent estimates of the percentage of clinical trial patients which appeared to have a probable causal relationship.</p><p>&nbsp;</p><p>Incidence greater than 1% - Probably Causally Related</p><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anesthesia/MAC Sedation</p></td><td style="vertical-align:top"><p>ICU Sedation</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Cardiovascular:</p></td><td style="vertical-align:top"><p>Bradycardia</p></td><td rowspan="5" style="vertical-align:top"><p>Bradycardia</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Decreased Cardiac Output</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>Hypotension 26%</p></td></tr><tr><td style="vertical-align:top"><p>Arrhythmia [Peds: 1.2%]</p></td></tr><tr><td style="vertical-align:top"><p>Tachycardia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nodal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [Peds: 1.6%]</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension* [Peds: 17%](see also&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL</p><p>PHARMACOLOGY)</p></td></tr><tr><td style="vertical-align:top"><p>Hypertension [Peds: 8%]</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Central Nervous System:</p></td><td colspan="3" style="vertical-align:top"><p>Movement* [Peds: 17%]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection Site:</p></td><td style="vertical-align:top"><p>Burning/Stinging 17.6% [Peds:10%]</p></td><td style="vertical-align:top"><p>or</p></td><td style="vertical-align:top"><p>Pain,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic/Nutritional:</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperlipemia*</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory:</p></td><td colspan="3" style="vertical-align:top"><p>Apnea</p><p>(see&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; also&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; CLINICAL PHARMACOLOGY)</p></td><td style="vertical-align:top"><p>Respiratory&nbsp;&nbsp;&nbsp; Acidosis&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; During Weaning*</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Appendages:</p></td><td style="vertical-align:top"><p>Rash&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; [Peds: Pruritus [Peds: 2%]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>5%]</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>Events without an * or % had an incidence of 1% to 3%</p><p>&nbsp;</p><p>&nbsp;</p><p>*Incidence of events 3% to 10%</p><p>&nbsp;</p><p>&nbsp;</p><p>Incidence less than 1% - Probably Causally Related</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anesthesia MAC Sedation</p></td><td style="vertical-align:top"><p>ICU Sedation</p></td></tr><tr><td style="vertical-align:top"><p>Body as a Whole:</p></td><td style="vertical-align:top"><p>Anaphylaxis/Anaphylactoid Reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Perinatal&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Disorder Tachycardia</p><p>Bigeminy Bradycardia</p><p>Premature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ventricular Contractions</p><p>Hemorrhage</p><p>ECG&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arrhythmia&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrial Fever</p><p>Extremities&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pain</p><p>Anticholinergic Syndrome</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular:</p></td><td style="vertical-align:top"><p>Premature Atrial Contractions Syncope</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Central Nervous System:</p></td><td style="vertical-align:top"><p>Hypertonia/Dystonia, Paresthesia</p></td><td style="vertical-align:top"><p>Agitation</p></td></tr><tr><td style="vertical-align:top"><p>Digestive:</p></td><td style="vertical-align:top"><p>Hypersalivation Nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hemic/Lymphatic:</p></td><td style="vertical-align:top"><p>Leukocytosis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection Site:</p></td><td style="vertical-align:top"><p>Phlebitis Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic:</p></td><td style="vertical-align:top"><p>Hypomagnesemia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal:</p></td><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nervous:</p></td><td style="vertical-align:top"><p>Dizziness Agitation Chills Somnolence Delirium</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory:</p></td><td style="vertical-align:top"><p>Wheezing Cough Laryngospasm Hypoxia</p></td><td style="vertical-align:top"><p>Decreased lung infection</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Skin and Appendages:</p></td><td style="vertical-align:top"><p>Flushing, Pruritus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Special Senses:</p></td><td style="vertical-align:top"><p>Amblyopia Vision Abnormal</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Urogenital:</p></td><td style="vertical-align:top"><p>Cloudy Urine</p></td><td style="vertical-align:top"><p>Green urine</p></td></tr></tbody></table><p>Incidence less than 1% - Causal Relationship Unknown</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anesthesia/MAC Sedation</p></td><td style="vertical-align:top"><p>ICU Sedation</p></td></tr><tr><td style="vertical-align:top"><p>Body as a Whole:</p></td><td style="vertical-align:top"><p>Asthenia, Awareness, Chest Pain, Extremities Pain, Fever, Increased Drug&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Effect,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neck Rigidity/Stiffness,</p><p>Trunk Pain</p></td><td style="vertical-align:top"><p>Fever, Sepsis, Trunk Pain, Whole Body Weakness</p></td></tr><tr><td style="vertical-align:top"><p>Cardiovascular:</p></td><td style="vertical-align:top"><p>Arrhythmia, Atrial Fibrillation, Atrioventricular Heart Block, Bigeminy, Bleeding, Bundle Branch Block, Cardiac Arrest, ECG</p><p>Abnormal, Edema, Extrasystole, Heart</p><p>Block, Hypertension, Myocardial Infarction, Myocardial Ischemia, Premature&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ventricular Contractions,</p><p>ST Segment Depression, Supraventricular Tachycardia, Tachycardia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ventricular Fibrillation</p></td><td style="vertical-align:top"><p>Arrhythmia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Atrial Fibrillation,</p><p>Bigeminy, Cardiac Arrest, Extrasystole, Right Heart Failure,</p><p>Ventricular Tachycardia</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Central Nervous System:</p></td><td colspan="2" style="vertical-align:top"><p>Abnormal&nbsp;&nbsp;&nbsp;&nbsp; Dreams,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Agitation, Amorous&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Behavior,&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anxiety, Bucking/Jerking/Thrashing, Chills/Shivering/Clonic/Myoclonic Movement,&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Combativeness, Confusion, Delirium, Depression, Dizziness,&nbsp;&nbsp;&nbsp; Emotional&nbsp;&nbsp;&nbsp;&nbsp; Lability, Euphoria, Fatigue, Hallucinations, Headache,&nbsp;&nbsp; Hypotonia,&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hysteria, Insomnia, Moaning, Neuropathy, Opisthotonos, Rigidity, Seizures, Somnolence, Tremor, Twitching</p></td><td colspan="3" style="vertical-align:top"><p>Chills/Shivering, Intracranial Hypertension,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Seizures,</p><p>Somnolence,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thinking Abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Digestive:</p></td><td colspan="2" style="vertical-align:top"><p>Cramping, Diarrhea, Dry Mouth, Enlarged Parotid, Nausea, Swallowing,Vomiting</p></td><td style="vertical-align:top"><p>Ileus, Abnormal</p></td><td style="vertical-align:top"><p>Liver</p></td><td style="vertical-align:top"><p>Function</p></td></tr><tr><td style="vertical-align:top"><p>Hematologic/Lymphatic:</p></td><td style="vertical-align:top"><p>Coagulation Leukocytosis</p></td><td style="vertical-align:top"><p>Disorder,</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection Site:</p></td><td style="vertical-align:top"><p>Hives/Itching, Redness/Discoloration</p></td><td style="vertical-align:top"><p>Phlebitis,</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Metabolic/Nutritional:</p></td><td colspan="2" style="vertical-align:top"><p>Hyperkalemia, Hyperlipemia</p></td><td colspan="3" style="vertical-align:top"><p>BUN&nbsp;&nbsp;&nbsp; Increased,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Creatinine Increased,</p><p>Dehydration,</p><p>Hyperglycemia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Metabolic Acidosis,</p><p>Osmolality Increased</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>Respiratory:</p></td><td colspan="3" style="vertical-align:top"><p>Bronchospasm, Burning in Throat, Cough, Dyspnea, Hiccough, Hyperventilation, Hypoventilation, Hypoxia,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laryngospasm, Pharyngitis,</p><p>Sneezing, Tachypnea, Upper Airway</p><p>Obstruction</p></td><td style="vertical-align:top"><p>Hypoxia</p></td></tr><tr><td style="vertical-align:top"><p>Skin and Appendages:</p></td><td style="vertical-align:top"><p>Conjunctival Diaphoresis, Urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyperemia,</p></td><td style="vertical-align:top"><p>Rash</p></td></tr><tr><td style="vertical-align:top"><p>Special Senses:</p></td><td style="vertical-align:top"><p>Diplopia,&nbsp;&nbsp; Ear Nystagmus, Tinnitus</p></td><td style="vertical-align:top"><p>Pain, Taste</p></td><td style="vertical-align:top"><p>Eye&nbsp;&nbsp; Pain, Perversion,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Urogenital:</p></td><td colspan="3" style="vertical-align:top"><p>Oliguria, Urine Retention</p></td><td style="vertical-align:top"><p>Kidney failure</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions (see details below)</p><p><u>Reporting of suspected adverse reactions</u></p><p>&nbsp;</p><p>&bull;&nbsp; Saudi Arabia<em>:</em></p><p>&nbsp;</p><p><strong><em>&nbsp;</em></strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><span style='mso-element:
field-begin;mso-field-lock:yes'></span><span style='mso-spacerun:yes'> </span>SHAPE
<span style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:
field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='width:383.8pt;
 height:129pt;mso-left-percent:-10001;mso-top-percent:-10001;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:char;
 mso-position-vertical:absolute;mso-position-vertical-relative:line;
 mso-left-percent:-10001;mso-top-percent:-10001' filled="f" strokeweight=".16969mm">
 <v:textbox inset="0,0,0,0">
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoBodyText style='margin-top:0in;margin-right:68.25pt;margin-bottom:
    0in;margin-left:5.15pt;margin-bottom:.0001pt;line-height:150%'><a
    name=Overdose></a><a name="Pharmacological_properties_"></a>The National
    Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662<o:p></o:p></p>
    <p class=MsoBodyText style='margin-left:5.15pt'>o Call NPC at
    +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:6.65pt;margin-right:0in;margin-bottom:
    0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
    mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
    style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span>Toll free phone:<span style='letter-spacing:-.1pt'> </span>8002490000<o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:6.85pt;margin-right:0in;margin-bottom:
    0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
    mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
    style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span>E-mail:<span style='letter-spacing:-.05pt'> </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='color:blue;text-decoration:
    none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><o:p></o:p></p>
    <p class=MsoBodyText style='margin-top:6.95pt;margin-right:0in;margin-bottom:
    0in;margin-left:14.15pt;margin-bottom:.0001pt;text-indent:-9.05pt;
    mso-list:l0 level1 lfo1;tab-stops:14.2pt'><![if !supportLists]><span
    style='letter-spacing:-.05pt'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp; </span></span></span><![endif]><span
    dir=LTR></span>Website:<span style='letter-spacing:-.05pt'> </span><a
    href="http://www.sfda.gov.sa/npc"><span style='color:blue;text-decoration:
    none;text-underline:none'>www.sfda.gov.sa/npc</span></a><o:p></o:p></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="none"/>
 <w:anchorlock/>
</v:shape><![endif]--><img width="516" height="176" alt="Text Box: The National Pharmacovigilance and Drug Safety Centre (NPC) o Fax: +966-11-205-7662
o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
o	Toll free phone: 8002490000
o	E-mail: npc.drug@sfda.gov.sa
o	Website: www.sfda.gov.sa/npc
" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><span
style='font-size:10.0pt;mso-bidi-font-size:12.0pt'><v:shape id="_x0000_i1025"
 type="#_x0000_t75" style='width:383.8pt;height:129pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong><em>&nbsp;</em></strong></p><p><strong>o Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If overdosage occurs, PROPOFOL administration should be discontinued immediately. Overdosage is likely to cause cardiorespiratory depression. Respiratory depression should be treated by artificial ventilation with oxygen. Cardiovascular depression would require lowering of the patient&#39;s head and, if severe, use of plasma expanders and pressor agents.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacodynamic properties of Propofol are dependent upon the therapeutic blood Propofol concentrations. Steady-state Propofol blood concentrations are generally proportional to infusion rates. Undesirable side effects, such as cardiorespiratory depression, are likely to occur at higher blood concentrations which result from bolus dosing or rapid increases in infusion rates. An adequate interval (3 minutes to 5 minutes) must be allowed between dose adjustments in order to assess clinical effects.</p><p>The hemodynamic effects of PROPOFOL during induction of anesthesia vary. If spontaneous ventilation is maintained, the major cardiovascular effect is arterial hypotension (sometimes greater than a 30% decrease) with little or no change in heart rate and no appreciable decrease in cardiac output. If ventilation is assisted or controlled (positive pressure ventilation), there is an increase in the incidence and the degree of depression of cardiac output. Addition of an opioid, used as a premedicant, further decreases cardiac output and respiratory drive.</p><p>If anesthesia is continued by infusion of PROPOFOL, the stimulation of endotracheal intubation and surgery may return arterial pressure towards normal. However, cardiac output may remain depressed.</p><p>&nbsp;</p><p>Comparative clinical studies have shown that the hemodynamic effects of PROPOFOL during induction of anesthesia are generally more pronounced than with other intravenous (IV) induction agents.</p><p>Induction of anesthesia with PROPOFOL is frequently associated with apnea in both adults and pediatric patients. In adult patients who received PROPOFOL (2 mg/kg to 2.5 mg/kg), apnea lasted less than 30 seconds in 7% of patients, 30 seconds to 60 seconds in 24% of patients, and more than 60 seconds in 12% of patients. In pediatric patients from birth through 16 years of age assessable for apnea who received bolus doses of PROPOFOL (1 mg/kg to 3.6 mg/kg), apnea lasted less than 30 seconds in 12% of patients, 30 seconds to 60 seconds in 10% of patients, and more than 60 seconds in 5% of patients.</p><p>During maintenance of general anesthesia, PROPOFOL causes a decrease in spontaneous minute ventilation usually associated with an increase in carbon dioxide tension which may be marked depending upon the rate of administration and concurrent use of other medications (e.g., opioids, sedatives, etc.).</p><p>During monitored anesthesia care (MAC) sedation, attention must be given to the cardiorespiratory effects of PROPOFOL. Hypotension, oxyhemoglobin desaturation, apnea, and airway obstruction can occur, especially following a rapid bolus of PROPOFOL. During initiation of MAC sedation, slow infusion or slow injection techniques are preferable over rapid bolus administration. During maintenance of MAC sedation, a variable rate infusion is preferable over intermittent bolus administration in order to minimize undesirable cardiorespiratory effects. In the elderly, debilitated, or American Society of Anesthesiologists Physical Status (ASA-PS) III or IV patients, rapid (single or repeated) bolus dose administration should not be used for MAC sedation (see <u>WARNINGS</u>).</p><p>Clinical and preclinical studies suggest that PROPOFOL is rarely associated with elevation of plasma histamine levels.</p><p>Preliminary findings in patients with normal intraocular pressure indicate that PROPOFOL produces a decrease in intraocular pressure which may be associated with a concomitant decrease in systemic vascular resistance.</p><p>Clinical studies indicate that PROPOFOL when used in combination with hypocarbia increases cerebrovascular resistance and decreases cerebral blood flow, cerebral metabolic oxygen</p><p>&nbsp;</p><p>consumption, and intracranial pressure. PROPOFOL does not affect cerebrovascular reactivity to changes in arterial carbon dioxide tension (see <u>Clinical Trials, Neuroanesthesia</u>).</p><p>Clinical studies indicate that PROPOFOL does not suppress the adrenal response to ACTH.</p><p>Animal studies and limited experience in susceptible patients have not indicated any propensity of PROPOFOL to induce malignant hyperthermia.</p><p>Hemosiderin deposits have been observed in the livers of dogs receiving PROPOFOL containing 0.005% disodium edetate over a four-week period; the clinical significance of this is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of Propofol are well described by a three compartment linear model with compartments representing the plasma, rapidly equilibrating tissues, and slowly equilibrating tissues.</p><p>Following an IV bolus dose, there is rapid equilibration between the plasma and the brain, accounting for the rapid onset of anesthesia. Plasma levels initially decline rapidly as a result of both distribution and metabolic clearance. Distribution accounts for about half of this decline following a bolus of Propofol. However, distribution is not constant over time, but decreases as body tissues equilibrate with plasma and become saturated. The rate at which equilibration occurs is a function of the rate and duration of the infusion. When equilibration occurs there is no longer a net transfer of Propofol between tissues and plasma.</p><p>Discontinuation of the recommended doses of PROPOFOL after the maintenance of anesthesia for approximately one hour, or for sedation in the ICU for one day, results in a prompt decrease in blood Propofol concentrations and rapid awakening. Longer infusions (10 days of ICU sedation) result in accumulation of significant tissue stores of Propofol, such that the reduction in circulating Propofol is slowed and the time to awakening is increased.</p><p>By daily titration of PROPOFOL dosage to achieve only the minimum effective therapeutic concentration, rapid awakening within 10 minutes to 15 minutes can occur even after long-term administration. If, however, higher than necessary infusion levels have been maintained for a long time, Propofol redistribution from fat and muscle to the plasma can be significant and slow recovery.</p><p>The figure below illustrates the fall of plasma Propofol levels following infusions of various durations to provide ICU sedation.</p><p>&nbsp;</p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="image2.png" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="dip grf" style='width:203.5pt;height:126pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif"
  o:title="dip grf"/>
</v:shape><![endif]--><img width="271" height="168" alt="dip grf" src="file:///C:/Users/Lenovo/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p>&nbsp;</p><p>The large contribution of distribution (about 50%) to the fall of Propofol plasma levels following brief infusions means that after very long infusions a reduction in the infusion rate is appropriate by as much as half the initial infusion rate in order to maintain a constant plasma level. Therefore, failure to reduce the infusion rate in patients receiving PROPOFOL for extended periods may result in excessively high blood concentrations of the drug. Thus, titration to clinical response and daily evaluation of sedation levels are important during use of PROPOFOL infusion for ICU sedation.</p><p>Adults</p><p><strong>&nbsp;</strong></p><p>Propofol clearance ranges from 23 mL/kg/min to 50 mL/kg/min (1.6 L/min to 3.4 L/min in 70 kg adults). It is chiefly eliminated by hepatic conjugation to inactive metabolites which are excreted by the kidney. A glucuronide conjugate accounts for about 50% of the administered dose. Propofol has a steady-state volume of distribution (10-day infusion) approaching 60 L/kg in healthy adults. A difference in pharmacokinetics due to sex has not been observed. The terminal half-life of Propofol after a 10-day infusion is 1 day to 3 days.</p><p>Geriatrics</p><p><strong>&nbsp;</strong></p><p>With increasing patient age, the dose of Propofol needed to achieve a defined anesthetic end point (dose-requirement) decreases. This does not appear to be an age-related change in pharmacodynamics or brain sensitivity, as measured by EEG burst suppression. With increasing patient age, pharmacokinetic changes are such that, for a given IV bolus dose, higher peak plasma concentrations occur, which can explain the decreased dose requirement. These higher peak plasma concentrations in the elderly can predispose patients to cardiorespiratory effects including hypotension, apnea, airway obstruction, and/or arterial oxygen desaturation. The higher&nbsp; plasma levels reflect an age-related decrease in volume of distribution and intercompartmental clearance.</p><p>&nbsp;</p><p>Lower doses are therefore recommended for initiation and maintenance of sedation and anesthesia in elderly patients (see <u>DOSAGE AND ADMINISTRATION</u>).</p><p>Pediatrics</p><p><strong>&nbsp;</strong></p><p>The pharmacokinetics of Propofol were studied in children between 3 years and 12 years of age who received PROPOFOL for periods of approximately 1 hour to 2 hours. The observed distribution and clearance of Propofol in these children were similar to adults.</p><p>Organ Failure</p><p><strong>&nbsp;</strong></p><p>The pharmacokinetics of Propofol do not appear to be different in people with chronic hepatic cirrhosis or chronic renal impairment compared to adults with normal hepatic and renal function.&nbsp; The effects of acute hepatic or renal failure on the pharmacokinetics of Propofol have not been studied.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Anesthesia and Monitored Anesthesia Care (MAC) Sedation Pediatric Anesthesia</p><p>PROPOFOL was studied in clinical trials which included cardiac surgical patients. Most patients were 3 years of age or older. The majority of the patients were healthy ASA-PS I or II patients. The range of doses in these studies are described in Tables 1 and 2.</p><p>TABLE 1. PEDIATRIC INDUCTION OF ANESTHESIA</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Age range</strong></p></td><td style="vertical-align:top"><p><strong>Induction&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dose</strong></p><p><strong>Median (range)</strong></p></td><td style="vertical-align:top"><p><strong>Injection&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Duration</strong></p><p><strong>Median (range)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Birth through 16 years</p></td><td style="vertical-align:top"><p>2.5&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mg/kg</p><p>(1 mg/kg to 3.6 mg/kg)</p></td><td style="vertical-align:top"><p>20&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sec.</p><p>(6 sec to 45 sec)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>TABLE 2. PEDIATRIC MAINTENANCE OF ANESTHESIA</strong></p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Age range</strong></p></td><td style="vertical-align:top"><p><strong>Maintenance dose</strong></p></td><td style="vertical-align:top"><p><strong>Duration</strong></p></td></tr><tr><td style="vertical-align:top"><p>2 months to 2 years</p></td><td style="vertical-align:top"><p>199&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mcg/kg/min&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (82</p><p>mcg/kg/min&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to 394</p><p>mcg/kg/min)</p></td><td style="vertical-align:top"><p>65 minutes (12 minutes to 282 minutes)</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>&nbsp;</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>2 to 12 years</p></td><td style="vertical-align:top"><p>188&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mcg/kg/min&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (12</p><p>mcg/kg/min&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1,041 mcg/kg/min)</p></td><td style="vertical-align:top"><p>69 minutes (23 minutes to 374 minutes</p></td></tr><tr><td style="vertical-align:top"><p>&gt;12 through 16 years</p></td><td style="vertical-align:top"><p>161&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mcg/kg/min&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (84</p><p>mcg/kg/min&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to 359</p><p>mcg/kg/min)</p></td><td style="vertical-align:top"><p>69 minutes (26 minutes to 251 minutes)</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p><strong>Neuroanesthesia</strong></p><p><strong>&nbsp;</strong></p><p>PROPOFOL was studied in patients undergoing craniotomy for supratentorial tumors in two clinical trials. The mean lesion size (anterior/posterior x lateral) was 31 mm x 32 mm in one trial and 55 mm x 42 mm in the other trial respectively. Anesthesia was induced with a median PROPOFOL dose of</p><p>1.4 mg/kg (range: 0.9 mg/kg to 6.9 mg/kg) and maintained with a median maintenance PROPOFOL dose of 146 mcg/kg/min (range: 68 mcg/kg/min to 425 mcg/kg/min). The median duration of the PROPOFOL maintenance infusion was 285 minutes (range: 48 minutes to 622 minutes).</p><p>&nbsp;</p><p>PROPOFOL was administered by infusion in a controlled clinical trial to evaluate its effect on cerebrospinal fluid pressure (CSFP). The mean arterial pressure was maintained relatively constant over 25 minutes with a change from baseline of -4% &plusmn; 17% (mean &plusmn; SD). The change in CSFP was - 46% &plusmn; 14%. As CSFP is an indirect measure of intracranial pressure (ICP), PROPOFOL, when&nbsp; given by infusion or slow bolus in combination with hypocarbia, is capable of decreasing ICP independent of changes in arterial pressure.</p><p>&nbsp;</p><p>Intensive Care Unit (ICU) Sedation Adult Patients</p><p>PROPOFOL was compared to benzodiazepines and opioids in clinical trials involving ICU patients. Of these, 302 received PROPOFOL and comprise the overall safety database for ICU sedation.</p><p>&nbsp;</p><p>Across all clinical studies, the mean infusion maintenance rate for all PROPOFOL patients was 27 &plusmn; 21 mcg/kg/min. The maintenance infusion rates required to maintain adequate sedation ranged from</p><p>&nbsp;</p><p>2.8 mcg/kg/min to 130 mcg/kg/min. The infusion rate was lower in patients over 55 years of age (approximately 20 mcg/kg/min) compared to patients under 55 years of age (approximately 38 mcg/kg/min). Although there are reports of reduced analgesic requirements, most patients received opioids for analgesia during maintenance of ICU sedation. In these studies, morphine or fentanyl was used as needed for analgesia. Some patients also received benzodiazepines and/or neuromuscular blocking agents. During long-term maintenance of sedation, some ICU patients were awakened once or twice every 24 hours for assessment of neurologic or respiratory function.</p><p>&nbsp;</p><p>In Medical and Postsurgical ICU studies comparing PROPOFOL to benzodiazepine infusion or bolus, there were no apparent differences in maintenance of adequate sedation, mean arterial pressure, or laboratory findings. Like the comparators, PROPOFOL reduced blood cortisol during sedation while maintaining responsivity to challenges with adrenocorticotropic hormone (ACTH). Case reports from the published literature generally reflect that PROPOFOL has been used safely in patients with a history of porphyria or malignant hyperthermia.</p><p>&nbsp;</p><p>In hemodynamically stable head trauma patients ranging in age from 19 years to 43 years, adequate sedation was maintained with PROPOFOL or morphine. There were no apparent differences in adequacy of sedation, intracranial pressure, cerebral perfusion pressure, or neurologic recovery between the treatment groups. In literature reports of severely head-injured patients in Neurosurgical ICUs, PROPOFOL infusion and hyperventilation, both with and without diuretics, controlled intracranial pressure while maintaining cerebral perfusion pressure. In some patients, bolus doses resulted in decreased blood pressure and compromised cerebral perfusion pressure.</p><p>&nbsp;</p><p>PROPOFOL was found to be effective in status epilepticus which was refractory to the standard anticonvulsant therapies. For these patients, as well as for ARDS/respiratory failure and tetanus patients, sedation maintenance dosages were generally higher than those for other critically ill patient populations.</p><p>&nbsp;</p><p>Pediatric Patients</p><p>&nbsp;</p><p>A single, randomized, controlled, clinical trial that evaluated the safety and effectiveness of PROPOFOL versus standard sedative agents (SSA) was conducted on 327 pediatric ICU patients. Patients were randomized to receive either PROPOFOL 2%, (113 patients), PROPOFOL 1%, (109 patients), or an SSA (e.g., lorazepam, chloral hydrate, fentanyl, ketamine, morphine, or phenobarbital). PROPOFOL therapy was initiated at an infusion rate of 5.5 mg/kg/hr and titrated as needed to maintain sedation at a standardized level. The results of the study showed an increase in the number of deaths in patients treated with PROPOFOL as compared to SSAs. Of the 25 patients who died during the trial or within the 28-day follow-up period: 12 (11% were) in the PROPOFOL 2% treatment group, 9 (8% were) in the PROPOFOL 1% treatment group, and 4% were (4%) in the SSA treatment group. The differences in mortality rate between the groups were not statistically significant. Review of the deaths failed to reveal a correlation with underlying disease status or a correlation to the drug or a definitive pattern to the causes of death.</p><p>&nbsp;</p><p>Cardiac Anesthesia</p><p><strong>&nbsp;</strong></p><p>PROPOFOL was evaluated in clinical trials involving patients undergoing coronary artery bypass graft (CABG).</p><p>&nbsp;</p><p>In post-CABG (coronary artery bypass graft) patients, the maintenance rate of Propofol administration was usually low (median 11 mcg/kg/min) due to the intraoperative administration of high opioid doses. Patients receiving PROPOFOL required 35% less nitroprusside than midazolam patients. During initiation of sedation in post-CABG patients, a 15% to 20% decrease in blood pressure was seen in the first 60 minutes. It was not possible to determine cardiovascular effects in patients with severely compromised ventricular function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Refined Soya bean Oil IV, Glycerol Anhydrous, Purified egg yolk lecithin, Edetate disodium, Sodium Hydroxide and water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The neuromuscular blocking agents, atracurium and mivacurium should not be given through the same intravenous line as Propofol Injectable Emulsion USP 200mg/20mL without prior flushing.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 Months
Shelf life after dilution
Use of diluted Propofol injectable emulsion must begin immediately following dilution.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&ordm;C.</p><p>Administration with Other Fluids</p><p>Compatibility of PROPOFOL with the coadministration of blood/serum/plasma has not been established (see <u>WARNINGS</u>). When administered using a y-type infusion set, PROPOFOL has been shown to be compatible with the following intravenous fluids.</p><p>-&nbsp; 5% Dextrose Injection, USP</p><p>-&nbsp; Lactated Ringers Injection, USP</p><p>-&nbsp; Lactated Ringers and 5% Dextrose Injection</p><p>-&nbsp; 5% Dextrose and 0.45% Sodium Chloride Injection, USP</p><p>-&nbsp; 5% Dextrose and 0.2% Sodium Chloride Injection, USP</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Vial pack</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>1.1&nbsp;&nbsp; General</p><p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.</p><p>Clinical experience with the use of in-line filters and PROPOFOL during anesthesia or ICU/MAC sedation is limited. PROPOFOL should only be administered through a filter with a pore size of 5 micron or greater unless it has been demonstrated that the filter does not restrict the flow of PROPOFOL and/or cause the breakdown of the emulsion. Filters should be used with caution and where clinically appropriate. Continuous monitoring is necessary due to the potential for restricted flow and/or breakdown of the emulsion.</p><p>Do not use if there is evidence of separation of the phases of the emulsion.</p><p>&nbsp;</p><p>Rare cases of self-administration of PROPOFOL by health care professionals have been reported, including some fatalities (see <u>DRUG ABUSE AND DEPENDENCE</u>).</p><p>Strict aseptic technique must always be maintained during handling. PROPOFOL is a single access parenteral product (single patient infusion vial) which contains 0.005% disodium edetate to inhibit the rate of growth of microorganisms, up to 12 hours, in the event of accidental extrinsic contamination. However, PROPOFOL can still support the growth of microorganisms as it is not an antimicrobially preserved product under USP standards. Do not use if contamination is suspected. Discard unused drug product as directed within the required time limits. There have been reports in which failure to use aseptic technique when handling PROPOFOL was associated with microbial contamination of the product and with fever, infection/sepsis, other life-threatening illness, and/or death.</p><p>There have been reports, in the literature and other public sources, of the transmission of bloodborne pathogens (such as Hepatitis B, Hepatitis C, and HIV) from unsafe injection practices, and use of Propofol vials intended for single use on multiple persons. PROPOFOL vials are never to be accessed more than once or used on more than one person.</p><p>Propofol, with EDTA inhibits microbial growth for up to 12 hours, as demonstrated by test data for representative USP microorganisms.</p><p>Guidelines for Aseptic Technique for General Anesthesia/MAC Sedation</p><p>PROPOFOL must be prepared for use just prior to initiation of each individual anesthetic/sedative procedure. The vial rubber stopper should be disinfected using 70% isopropyl alcohol. PROPOFOL should be drawn into a sterile syringe immediately after a vial is opened. When withdrawing PROPOFOL from vials, a sterile vent spike should be used. The syringe should be labeled with appropriate information including the date and time the vial was opened. Administration should commence promptly and be completed within 12 hours after the vial has been opened.</p><p>PROPOFOL must be prepared for single-patient use only. Any unused PROPOFOL drug product, reservoirs, dedicated administration tubing and/or solutions containing PROPOFOL must be discarded at the end of the anesthetic procedure or at 12 hours, whichever occurs sooner. The IV line should be flushed every 12 hours and at the end of the anesthetic procedure to remove residual PROPOFOL.</p><p>&nbsp;</p><p>Guidelines for Aseptic Technique for ICU Sedation</p><p>PROPOFOL must be prepared for single-patient use only. Strict aseptic techniques must be followed. The vial rubber stopper should be disinfected using 70% isopropyl alcohol. A sterile vent spike and sterile tubing must be used for administration of PROPOFOL. As with other lipid emulsions, the number of IV line manipulations should be minimized. Administration should commence promptly and must be completed within 12 hours after the vial has been spiked. The tubing and any unused PROPOFOL drug product must be discarded after 12 hours.</p><p>If PROPOFOL is transferred to a syringe prior to administration, it should be drawn into a sterile syringe immediately after a vial is opened. When withdrawing PROPOFOL from a vial, a sterile vent spike should be used. The syringe should be labeled with appropriate information including the date and time the vial was opened. Administration should commence promptly and be completed within 12 hours after the vial has been opened. PROPOFOL should be discarded and administration lines changed after 12 hours.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Saudi Amarox Industrial Company,
Aljameah Street, Malaz quarter, Riyadh 11441, Saudi Arabia
Tel: +966 11 477 2215
Manufacture: Aspiro Pharma Limited, Hyderabad, India

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April, 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>